**UNITED
      STATES**


**SECURITIES
      AND EXCHANGE COMMISSION**


**Washington,
      D.C. 20549**


______________




**FORM
      10-KSB**




**x**  **ANNUAL
      REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES** **EXCHANGE
      ACT OF 1934**




**For
      the annual period ended December 31, 2005**




**o**  **TRANSITION
      REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES** **EXCHANGE
      ACT OF 1934**




For
      the
      transition period from _________ to _________




**HUIFENG
      BIO-PHARMACEUTICAL TECHNOLOGY, INC.**


______________




(Name
      of
      Small Business Issuer in Its Charter)




NEVADA
            Commission
                File No:
            87-0650264(State
                or other jurisdiction of incorporation or organization)
            000-32253
            (I.R.S.
                Employer Identification No.)16B/F
                Ruixin Road Bldg. No. 25 Gaoxin Road Xi An 710075 Shaanxi Province,
                China(Address
                of principal executive offices)(86)
                29 8824 6358(Issuer's
                telephone number, including area
                code)





**Securities
      Registered Pursuant to Section 12(b) of the Act: None**




**Securities
      Registered Pursuant to Section 12(g) of the Act:**




**Common
      Stock, Par Value $0.018 Per Share**


**(Title
      of Class)**




Check
      whether the issuer (1) filed all reports required to be filed by Section 13
      or
      15(d) of the exchange Act during the past 12 months (or for such shorter period
      that the registrant was required to file such reports); and (2) has been subject
      to such filing requirements for the past 90 days.




Yes
xNo
o




Check
      if
      there is no disclosure of delinquent filers in response to Item 405 of
      Regulation S-B contained in this form, and no disclosure will be contained,
      to
      the best of registrant’s knowledge, in definite proxy or information statements
      incorporated by reference in Part III of this form 10-KSB or any amendment
      to
      this Form 10-KSB. o




The
      issuer’s revenues for the fiscal year ended December 31, 2005 were
      $2,443,060.




The
      aggregate market value of the common stock held by non-affiliates as of March
      31, 2006 was $3,084,084




State
      the
      number of shares outstanding of each of the issuer's classes of equity
      securities, as of the latest practicable date:




Title
                of Each Class of Equity Securities
            
            Number
                of Shares Outstanding as of December 31, 2005Common
                Stock, $0.018 par value
            
            15,666,169




Transitional
      Small Business Disclosure Format (check one): Yes o No x









TABLE
      OF
      CONTENTS








PagePART
                IITEM
                1.Description
                of Business
            2ITEM
                2.Description
                of Properties
            7ITEM
                3.Legal
                Proceedings
            7ITEM
                4.Submission
                of Matters to a Vote of Security Holders
            7PART
                IIITEM
                5.Market
                for Common Equity and Related Stockholder Matters
            8ITEM
                6.Management’s
                Discussion and Analysis
            9ITEM
                7.Financial
                Statements
            13ITEM
                8.Changes
                in and Disagreements with Accountants on Accounting and Financial
                Disclosures
            13ITEM
                8A.Controls
                and Procedures
              ITEM
                8B. Other Information
            14PART
                IIIITEM
                9.Directors,
                Executive Officers, Promoters and Control Persons, Compliance With
                Section
                16(A) of the Exchange Act
            14ITEM
                10. Executive Compensation
            15ITEM
                11. Security Ownership of Certain Beneficial Owners and
                Management
            15ITEM
                12. Certain Relationships and Related Transactions
            16ITEM
                13. Exhibits
            16ITEM
                14. Principal Accounting Fees and Services
            16





ii


This
      annual report contains certain forward-looking statements within the meaning
      of
      Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
      Securities Exchange Act of 1934, as amended. These include statements about
      our
      expectations, beliefs, intentions or strategies for the future, which we
      indicate by words or phrases such as "anticipate," "expect," "intend," "plan,"
      "will," "we believe," "our company believes," "management believes" and similar
      language. These forward-looking statements are based on our current expectations
      and are subject to certain risks, uncertainties and assumptions, including
      those
      set forth in the discussion under Item 1. “Description of Business" and Item 6.
      "Management's Discussion and Analysis", including under the heading “- Risk
      Factors” under Item 6. Our actual results may differ materially from results
      anticipated in these forward-looking statements. We base our forward-looking
      statements on information currently available to us, and we assume no obligation
      to update them. In addition, our historical financial performance is not
      necessarily indicative of the results that may be expected in the future and
      we
      believe that such comparisons cannot be relied upon as indicators of future
      performance.




Certain
      financial information included in this annual report has been derived from
      data
      originally prepared in Renminbi (RMB), the currency of the People’s Republic of
      China. For purposes of this annual report, a conversion rate of US$1.00 to
      RMB 8.3 was
      utilized. There is no assurance that RMB amounts could have been or could be
      converted into US dollars at that rate.




Huifeng
      Bio-Pharmaceutical Technology, Inc., through its subsidiary Northwest BioTechnic
      Inc. ("NBTI") owns and operates, Huifeng Biochemistry Joint Stock Company
      ("Huifeng"), which is a joint venture company established under the laws of
      the
      People's Republic of China ("PRC" or “China”) with its main business as
      production and sales of plant extracts, biochemical products and pharmaceutical
      raw products in the PRC.









**PART
      I**




**ITEM
      1.**  **DESCRIPTION
      OF BUSINESS**




**HISTORY**




Our
      company, HUIFENG BIO-PHARMACEUTICAL TECHNOLOGY, INC. (“we”, “us”, “our”, “HFGB”,
      the ”Company” or “our Company”), was incorporated under the laws of the State of
      Nevada and trades on the Over the Counter ("OTC") Bulletin Board under the
      symbol "HFGB".




HUIFENG
      BIO-PHARMACEUTICAL TECHNOLOGY, INC. is a corporation formed under the laws
      of
      the State of Nevada on March 16, 2000. During the year 2000, we acquired a
      license to market VitaMineralHerb.com products to customers in Oklahoma and
      New
      Mexico. VitaMineralHerb.com hosts an Internet web site where health related
      products can be purchased for resale; the web site then automatically credits
      the licensee with purchases from their customers. We did not generate any
      revenues from the above endeavors and during March 2002, we decided to terminate
      our involvement with marketing vitamins and such related projects; consequently,
      we cancelled our license agreement with VitaMineralHerb.com. Since
      October 2002, management's business plan was to seek out a privately held
      business with whom the Company can reorganize so as to take advantage of the
      Company's status as a publicly held corporation.





On
      December 20, 2004, pursuant to the terms of a Stock Purchase Agreement ("Malone
      Agreement"), Art Malone, Jr. ("Selling Shareholder") sold 7,229,601 shares
      of
      the common stock of Secured Data, Inc. ("Company") for $300,000 (the "Sale")
      to
      Zhi Lan Wang and Jun Lin, individuals. As a result, the 7,229,601 shares of
      the
      common stock of the Company sold represented approximately 56.18% of the total
      outstanding stock of the Company. Immediately thereafter, pursuant to the terms
      of an Agreement and Plan of Reorganization dated December 20, 2004 ("Northwest
      Agreement"), the Company initially purchased 30% of the common shares of
      Northwest BioTechnic Inc. ("NBTI"), a British Virgin Islands corporation, in
      exchange for 80,735,590 shares of the Company's common stock ("Acquisition").
      The purchase price for the remaining 70% of NBTI's common shares was $1,900,000
      payable by the Company's issuance of a promissory note ("Promissory Note")
      on
      December 20, 2004. The Promissory Note was subsequently converted into
      10,465,725 (post a one for eighteen reverse split) shares of the Company's
      common stock. As a result, the 80,735,590 shares of the common stock of the
      Company sold represented approximately 86.3% of the total outstanding stock
      of
      the Company.




NBTI
      was
      incorporated in the British Virgin Islands on June 25, 2004. NBTI operates
      through its wholly owned subsidiary, Huifeng Biochemistry Joint Stock Company
      ("Huifeng"), which is a joint venture company established under the laws of
      the
      PRC and is a company engaging in the production and sales of plant extracts,
      biochemical products and pharmaceutical raw products in the PRC.




**BUSINESS
      OVERVIEW**




HFGB,
      through its wholly owned subsidiary NBTI, owns 100% of Huifeng which produces
      and sells plant extracts, biochemical products and pharmaceutical raw products
      in the PRC. Huifeng was founded on January 18, 2000. With its proprietary
      technology of “Producing Rutin by Eliminating Enzyme and Mucus” together with
      abundant resources of high quality pagoda rice in the Northwest region of China
      as raw material, Huifeng developed and specialized itself as one of the major
      technology based Rutin company in Xian city within two years after
      establishment. Huifeng possesses one of the most advanced and patented
      Rutin-refining technology in China and is a major Rutin supplier for the world
      market.




Huifeng
      emphasized technology and product innovation and its strategic mission is to
      commercialize Chinese traditional medicine.




In
      2005
      we achieved the business missions of the followings:









(a)
            Achieved
                sale revenues of $2,443,060;




(b)
            Researched,
                developed and commercialized two new products, Diosmin and
                L-Rhamnose;




(c)
            Rebuilt
                all supporting facilities of our production facilities after GMP
                modification.




**OUR
      PRODUCTS**




Huifeng
      produces a series of Rutin and Rutin related products:




Pharmaceutical
                Intermediates
            1.NF11
                Rutin (USP standard)
              2.DAB8、DAB9、DAB10、DAB11
                Rutin (German Codex Standard)
              3.Troxerutin
                (farinaceous injection、oral
                application)
              4.Quercetin,
                L-RhamnonePharmaceutical
                Material
            1.Venoruton
                (farinaceous injection、oral
                application)
              2.Rutin
              3.Berberine
                Hydrochloride
              4.Matrine
              5.Diosmin
              5.L-RhamnosePlant
                Extracts
            1.Hesperidin
              2.Naringin
              3.Epimedium
                Extract
              4.Matrine
              5.Puerorin
              6.Siybun
                Marianum P.E


The
      chemical name of Rutin is rue glycoside (Molecular formula: C 27 H 30 O 163 H 2O )
      and it
      is a kind of plant extract. It can inhibit platelet aggregation and prevent
      thrombosis. It can also improve the permeability of capillary vessels, and
      has
      the properties of:




1.
            Anti
                - inflammatory;




2.
            Decreasing
                blood pressure and fat; and




3.
            Mitigating
                cerebral hemorrhage.




Also,
      it
      has positive effect in protecting heart and cerebral hemorrhage and
      ischemia-reperfusion injury. It is widely used as a raw material for the heart
      and cerebral blood vessel medicines as well as an additive for cosmetics and
      functional food. The demand for Rutin increases at an annual rate of
      approximately 30% due to the increased demand for heart and cerebral blood
      vessel medicines as a result of the aging population. Furthermore, the
      improvement in living standards in China also stimulates the growth in the
      demand for functional food and natural cosmetics.




During
      2005 we developed two new products, Diosmin and L-Rhamnose.




The
      chemical name of Diosmin is 7-[[6-o(6-Deoxy-2-L-mannopyranosyl)- β-D-glucopyran -osyl]oxy]-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-l-ben-zopyran-4-one).
      Diosmin is a pharmaceutical material, which has comprehensive impact on blood
      vessel feedback system and is suitable for treatment of acute or chronic
      hemorrhoids and chronic insufficiency of vein (lower limbs varicosity, dropsy
      and chronic canker)




The
      chemical name of L-Rhamnose is (thymidine-5’-diphosphate-L-rhamnose). Belonging
      to the category of monosackcharide, it is generally applied in manufacturing
      antivirus and anti-tumor raw medicines. In addition, this product can be an
      ingredient for food. It has been used for testing permeation of intestines
      and
      sweet additives. At present, L-Rhamnose is mostly applied in synthetic perfume
      of fruit spice. It is the basic material for fruit spice composition. L-Rhamnose
      has been widely applied in the industrial production and scientific research,
      such as intermediate synthetic perfumes and heart-strength medicines made from
      organic matters. Furthermore, as an ingredient for food, L-Rhamnose can be
      directly added into top-grade coffee, beverage or meat.









**PRODUCTION
      FACILITIES**




In
      2005
      we had two major production facilities and
      the
      equipment resources of each of the facilities were as follows:




1.
            Manufacturing
                plant located at NO 1,Huifeng Rd, Changwu,
                Xianyang:




·
            This
                production site is for refining and manufacturing of new
                products




·
            Has
                a total of ten buildings including:




·  A
      two
      levels office building


·  A
      four
      levels staff building


·  Three
      manufacturing buildings (including extract workshops, refining workshops and
      packaging workshops)


·  One
      raw
      materials storage building


·  One
      building for storage of finished products


·  One
      building for dangerous products


·  Building
      for power and maintenance (including boiler, power distribution and
      maintenance)


·  One
      cafeteria and staff canteen







2.
            Manufacturing
                plant located in Fenghui, Changan,
                Xian




·
            This
                production site is for the extraction and supplies of raw materials
                for
                refining




·
            Has
                a total of four buildings including:




·  One
      office building


·  One
      manufacturing building (including extract workshops, crystallization workshops,
      communication workshops and packaging workshops),


·  One
      raw
      materials building


·  One
      boiler




The
      two
      production facilities together occupy a total area of approximately 300,000
      square feet.





In
      2005
      we operated 3 production lines: Plant extract production line, pharmaceutical
      raw medicines production line and refining processing production line.




Plant
      extract production line separated the essence of plants through extraction
      to
      produce pharmaceutical raw medicines that can be sold to our customers as final
      product (Plant extracts) or as raw materials for our further processing.




Pharmaceutical
      raw medicines production line extracted, compounded and processed all
      pharmaceutical raw medicines.




Refining
      processing production line produced pharmaceutical raw medicines from raw
      materials through extraction process.




In
      2005
      we constructed two new workshops for our refining processing product line for
      manufacturing of Diosmin and L-Rhamnose. We also purchased multiple
      concentration evaporators, condensers, reaction vessels, centrifuges equipment,
      new tri-effect concentrations and multifunctional extraction tank to improve
      the
      production quality and efficiency of our production lines.




**TARGET
      MARKETS AND PRINCIPAL CUSTOMERS**




There
      was
      no change in the target customers of our Company. Our existing products and
      new
      products launched during 2005 are all raw materials intermediaries for
      production of medicines and the users of these products are industrial clients.
      As a result, Huifeng’s main target customers are pharmaceutical companies and
      food manufacturers.













**SALES
      AND MARKETING**




In
      2005,
      there was no change in our target market and the majority of our products are
      still raw materials and intermediaries for production of medicines. Our target
      customers are mostly industrial clients and we continue to sell and distribute
      our products through direct selling to medicine and food manufacturers. These
      customers placed purchase orders directly with our sales and marketing team.
      Our
      sales department was divided into two teams, domestic sales team and export
      sales team. Our domestic sales team was responsible for domestic market while
      export sales team was responsible for international market
      customers.




There
      were two changes in the structure of our sales team in 2005. We increased one
      employee in our domestic sales department and enrolled two new staffs in our
      export sales department. As a result, we increase the total staff forces of
      our
      whole sales departments to sixteen people. Furthermore, we subdivided our export
      sales department into two sections: Export section I for European and West-Asia
      businesses export section II for America, eastern and southern Asia. As a
      result, our sales department restructured into four divisions by functions,
      namely domestic sales team, export section I, export section II and servicing
      department.




In
      2005,
      in order to diversify and expand our product sales networks, we started to
      expand to outside distribution channel for some of our export sales. We accepted
      purchase orders from professional foreign trade corporations in order to expand
      our international distribution channels and increase the sale revenues from
      exports.




We
      did
      not establish any regional representative or sale office in 2005 because our
      products were sold through direct orders from our clients with our sales
      department. There was no need for any retail distribution of our product and
      as
      a result we did not need any regional sales office.




**COMPETITION**




Huifeng
      engages in Rutin production in China. With its proprietary technology of
“Producing Rutin by Eliminating Enzyme and Mucus” and with abundant resources of
      high quality pagoda rice in the Northwest region of China as raw material,
      Huifeng does not face substantial competitions within China.




In
      2005
      our major competitor was still Sichuan Xietong Pharmaceutical Company Limited
      (“Xietong”). However, because of a lack of technological patents and the ready
      access to raw materials, Xietong is gradually fading out of the Rutin refining
      business and is shifting its business from raw medicine production to finished
      medicine production, and retains a rather small portion of its business in
      raw
      medicine production.




In
      2005
      there were still many small domestic Rutin manufacturers but these manufacturers
      did not impose any threat to our business and sometimes they even became our
      suppliers and supported our operations.




**PRINCIPAL
      OFFICE**




Our
      principal office is located at FL16B, Ruixin Building, NO.25, Gaoxin Rd, Xian
      China.




**EMPLOYEES
      AND ORGANIZATION**




As
      of
      December 31, 2004, we had approximately 186 full-time employees. During 2005,
      we
      employed 12 new employees. 4 new employees were recruited for our new Diosmin
      product line while another 4 were recruited for our new L-Rhamnose product
      line.
      2 additional staffs were allotted to our export sales team while 1 was added
      to
      our domestic sales team. As a result, by the end of 2005, we had a total of
      198
      employees. None of our employees are covered by a collective bargaining
      agreement and we have never experienced a work stoppage, and we consider our
      labor relations to be excellent.









As
      of
      December 31, 2005, our Company organization was
      as
      follow:




Department
            
            Employee
                as of end of 2005
            Employee
                as of end of 2004Sales
                department:Domestic
                sales department
            
            5
            4Export
                sales department:Export
                section I
            
            6
            9Export
                section II
            
            5
            0Production
                department
            
            143
            136Technical
                department
            
            9
            7Inspection
                department
            
            8
            8Provision
                department
            
            5
            5Personnel
                department
            
            5
            5Finance
                department
            
            6
            6Security
                department
            
            6
            6TOTAL
            
            198
            186




**BUSINESS
      DEVELOPMENT AND ACQUISITIONS**




In
      200 5
      we
      focused on new products and sales channels development. We successfully
      commercialized 2 new products and established new export sales channels. Looking
      forward to 2006 and 2007, we will focus on:




1.
            Commercializing
                additional two to three new pharmaceutical raw medicines and plant
                extracts products and striving to launch these products into the
                public
                market;




2.
            Increasing
                our market share in pharmaceutical raw medicines and plant extracts
                products in both international and domestic
                markets;




3.
            Streamlining
                our organization to ensure smooth operations and
                productions.




4.
            We
                plan to acquire one or two target enterprises in 2006, among which
                are
                valued-added assets of Huifeng Pharmacy and enterprises engaging
                in
                animal-breeding & agriculture of favorable market
                prospect.




**RESEARCH
      AND DEVELOPMENT**




In
      2005
      we focused ourselves on research and development of new products. We expanded
      our research and development team to include 2 professionals:




Shifeng
      Xin   apothecary
      executive; Biology Department, Northwest University




Ping
      Wang   apothecary
      executive; Biology Department, Northwest University




Looking
      forward to our research and development strategies in 2006, we will focus our
      research and development effort on pharmaceutical raw medicines and plant
      extracts with an aim to develop two to three new products within
      2006.




**PATENTS
      AND INTELLECTUAL PROPERTIES**




Huifeng’s
      proprietary technology “Producing Rutin by Eliminating Enzyme and Mucus”
received Chinese national technology patent with a 10 year protection
      period.




Although
      we developed two new products during 2005, we did not obtain any patent for
      our
      new products.









**GOVERNMENT
      REGULATIONS**




Chinese
      government requires all medicine and medicinal products related manufacturers
      to
      obtain GMP certification on their pharmaceutical manufacturing facilities.
      Huifeng obtained GMP certification from relevant government regulatory in
      January 1, 2005. Other than GMP certification requirements, there was no
      significant change in the regulatory environment in China.




**ITEM
      2.**  **DESCRIPTION
      OF PROPERTIES**




See “production
      facilities” in ITEM 1 - DESCRIPTION OF BUSINESS.




There
      is
      no lien or encumbrance on any of the mentioned properties.




**ITEM
      3**  **LEGAL
      PROCEEDINGS**




We
      are
      currently not involved in any litigation that we believe could have a material
      adverse effect on our financial condition or results of operations. There is
      no
      action, suit, proceeding, inquiry or investigation before or by any court,
      public board, government agency, self-regulatory organization or body pending
      or, to the knowledge of the executive officers of our company or any of our
      subsidiaries, threatened against or affecting our company, our common stock,
      any
      of our subsidiaries or of our company's or our company's subsidiaries' officers
      or directors in their capacities as such, in which an adverse decision could
      have a material adverse effect.




**ITEM
      4**  **SUBMISSION
      OF MATTERS TO A VOTE OF SECURITY HOLDERS**




On
      March
      23, 2005, the Board of Directors unanimously approved and ratified
      an 1:18
      reverse split (the "Reverse Split") of the Company's issued and outstanding
      common stock and an amendment (the "Amendment") to its Articles of Incorporation
      changing the name of the Company to "Huifeng Bio-pharmaceutical Technology
      Inc.", subject to the approval of the Company's stockholders. The record date
      established by the Board for purposes of determining the number of outstanding
      shares of voting stock entitled to vote on the Reverse Split and the Amendment
      was March 23, 2005 (the "Record Date"). On the Record Date, stockholders owning
      53,850,640 shares of Common Stock, or approximately 57.5% of the issued and
      outstanding shares of Common Stock, approved the Reverse Split and the Amendment
      by action taken without a meeting in accordance with Nevada law. No further
      vote
      of our stockholders was required.




As
      a
      result, the Company filed a preliminary information statement and definitive
      information statement pursuant to Section 14(c) of the Securities Exchange
      Act
      of 1934 on March 23, 2005 and September 13, 2005, respectively, in connection
      with the approval by a majority of the stockholders of (i) an amendment to
      its
      Articles of Incorporation effecting the Reverse Split and (ii) the Amendment




On
      October 12, 2005, the Reverse Split and the Amendment were declared effective.
      The number of issued and outstanding shares of our common stock was reduced
      from
      93,604,958 shares to 5,200,444 shares and our Company name was changed to
      "Huifeng Bio-pharmaceutical Technology Inc."









**PART
      II**




**ITEM
      5**  **MARKET
      FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS**




Our
      common stock is quoted on the Over-the-Counter Bulletin Board (“OTCBB”) under
      the symbol "HFGB”.




Trading
      in our common stock has been limited and sporadic. The following table shows
      the
      range of high and low bid quotations reported by the OTCBB in each fiscal
      quarter from January 1, 2004 to December 31, 2005, and the subsequent interim
      period. The OTCBB quotations reflect inter-dealer prices, without retail
      mark-up, mark-down or commission, and may not represent actual transactions.
      As
      of March 28, 2006, there were approximately 126 holders of record of our common
      stock. This number does not include an indeterminate number of shareholders
      whose shares are held by brokers in street name.





**BID
      PRICES FOR THE REPORTING PERIOD**




**Year**
            
            **Period**
            
            **High**
            
            **Low**2004
            
            
            First
                Quarter
            
            $
            0.300
            
            $
            0.010Second
                Quarter
            
            
            0.070
            
            
            0.060Third
                Quarter
            
            
            0.300
            
            
            0.050Fourth
                quarter
            
            
            0.590
            
            
            0.0202005
            
            
            First
                Quarter
            
            $
            0.160
            
            $
            0.050Second
                Quarter
            
            
            2.720
            
            
            0.720Third
                Quarter
            
            
            1.260
            
            
            0.540Fourth
                quarter
            
            
            2.150
            
            
            0.5802006
            
            
            First
                Quarter (through March 27, 2006)
            
            
            0.700
            
            
            0.370




**DIVIDENDS**




We
      presently intend to retain future earnings, if any, to provide funds for use
      in
      the operation and expansion of our business. Accordingly, we have not declared
      or paid any dividends to our common shareholders and do not presently intend
      to
      do so. Any future decision whether to pay dividends will depend on our financial
      condition and any other factors that our Board of Directors deems
      relevant.




**ISSUANCE
      OF SHARES**




On
      September 13, 2005 we filed an information statement pursuant to section 14(c)
      of the Securities Exchange Act of 1934 to approve a reverse Split that resulted
      in a reduction of our number of issued and outstanding shares from 93,604,958
      to
      approximately 5,200,444 shares. As of the effective date of the Reverse Split,
      each previously outstanding share shall be reduced to 0.0556 shares. Subsequent
      to the reverse split, we issued 10,465,725 shares of our restricted common
      stock
      at $0.1815 per share to repay to the holders of a convertible promissory note
      with a principal sum of $1,900,000.




On
      December 29, 2005, we filed a Form S-8 registration statement under the
      Securities Act of 1933 to register 800,000 shares of our common stocks to four
      individuals. As of December 31, 2005 and the date of this report, we did not
      issue any of these shares.




Unless
      otherwise noted, the sales set forth above involved no underwriter's discounts
      or commissions and are claimed to be exempt from registration with the
      Securities and Exchange Commission pursuant to Section 4 (2) of the Securities
      Act of 1933, as amended, as transactions by an issuer not involving a public
      offering, the issuance and sale by the Company of shares of its common stock
      to
      financially sophisticated individuals who are fully aware of the Company's
      activities, as well as its business and financial condition, and who acquired
      said securities for investment purposes and understood the ramifications of
      same.











**ITEM
      6**  **MANAGEMENT’S
      DISCUSSIONS AND ANALYSIS**




This
      annual report contains forward-looking statements within the meaning of the
      federal securities laws. These include statements about our expectations,
      beliefs, intentions or strategies for the future, which we indicate by words
      or
      phrases such as "anticipate," "expect," "intend," "plan," "will," "we believe,"
      "HFGB believes," "management believes" and similar language. The forward-looking
      statements are based on the current expectations of HFGB and are subject to
      certain risks, uncertainties and assumptions, including those set forth in
      the
      discussion under "Description of Business" and "Management's Discussion and
      Analysis or Plan of Operation,". The actual results may differ materially from
      results anticipated in these forward-looking statements. We base the
      forward-looking statements on information currently available to us, and we
      assume no obligation to update them.




On
      December 20, 2004, pursuant to the Malone Agreement, Art Malone, Jr. ("Selling
      Shareholder") sold 7,229,601 shares of the common stock of the Company for
      $300,000 (the "Sale") to Zhi Lan Wang and Jun Lin, individuals on the closing
      date of December 20, 2004. As a result, the 7,229,601 shares of the common
      stock
      of the Company sold represented approximately 56.18% of the total outstanding
      stock of the Company. Immediately thereafter, On December 20, 2004 HFGB
      completed a Northwest Agreement, of which the Company initially purchased 30%
      of
      the common shares of NBTI in exchange for 80,735,590 shares of the Company's
      common stock ("Acquisition"). The purchase price for the remaining 70% of NBTI's
      common shares was $1,900,000 payable by the Company's issuance of a promissory
      note ("Promissory Note") on December 20, 2004 The Promissory Note may be
      convertible into 10,465,725 (post a one for eighteen reverse split) shares
      of
      the Company's common stock. As a result, the 80,735,590 shares of the common
      stock of the Company sold represented approximately 86.3% of the total
      outstanding stock of the Company. The Exchange resulted in a change of voting
      control of the Company.




NBTI
      was
      incorporated in the British Virgin Islands on June 25, 2004. NBTI operates
      through its wholly owned subsidiary, Huifeng Biochemistry Joint Stock Company
      ("Huifeng"), which is a joint venture company established under the laws of
      China and is engaged in the production and sales of plant extracts, biochemical
      products and pharmaceutical raw products in the PRC.




The
      exchange was treated as a reverse acquisition for accounting purposes. As such,
      the financial information reflected activity subsequent to the acquisition
      for
      HFGB and its subsidiaries and financial activity of NBTI prior to the
      acquisition. We will continue the business operations conducted by NBTI.




**CRITICAL
      ACCOUNTING POLICIES AND ESTIMATES**




We
      have
      identified one policy area as critical to the understanding of our consolidated
      financial statements. The preparation of our consolidated financial statements
      requires management to make estimates and assumptions that affect the reported
      amounts of assets and liabilities and disclosure of contingent assets and
      liabilities at the date of the consolidated financial statements and the
      reported amounts of sales and expenses during the reporting periods. With
      respect to net realizable value of the Company's accounts receivable and
      inventories, significant estimation judgments are made and actual results could
      differ materially from these estimates.




The
      Company does not have any reserves against its accounts receivable or
      inventories at December 31, 2005 and 2004. Management's estimation that there
      are no reserves is based on the current facts that there is no significant
      aged
      accounts receivable and the current inventory turnover is sufficient to realize
      the current carrying value of the inventories. In making their judgment,
      management has assumed that there will be continued demand for their products
      in
      the future, thereby maintaining adequate turnover of the inventories.
      Additionally, management has assumed that customers will continue to pay their
      outstanding invoices timely, and that their customers' financial position will
      not deteriorate significantly in the future, which would result in their
      inability to pay their debts to the Company. While the Company's management
      currently believes that there is little likelihood that the actual results
      of
      their current estimates will differ materially from its current estimates,
      if
      customer demand for its products decreases significantly in the near future,
      or
      if the financial position of its customers deteriorates in the near future,
      the
      Company could realize significant write downs for slow moving inventories or
      uncollectible accounts receivable.













We
      believe the following is among the most critical accounting policies that impact
      our consolidated financial statements. We suggest that our significant
      accounting policies, as described in our consolidated financial statements
      in
      the Summary of Significant Accounting Policies, be read in conjunction with
      this
      Management's discussion and Analysis of Financial Condition and Results of
      Operations.




We
      recognize revenue in accordance with Staff Accounting Bulletin ("SAB") No.
      104.
      All of the following criteria must exist in order for us to recognize
      revenue:




1.
      Persuasive evidence of an arrangement exists;




2.
      Delivery has occurred or services have been rendered;




3.
      The
      seller's price to the buyer is fixed or determinable and




4.
      Collectibility is reasonably assured.




The
      majority of the Company's revenue results from sales contracts with distributors
      and revenue is generated upon the shipment of goods. The Company's pricing
      structure is fixed and there are no rebate or discount programs. Management
      conducts credit background checks for new customers as a means to reduce the
      subjectivity of assuring collectibility. Based on these factors, the Company
      believes that it can apply the provisions of SAB 104 with minimal
      subjectivity.




**RESULTS
      OF OPERATIONS**




The
      following table sets forth selected statement of operations data as a percentage
      of revenues for the periods indicated.




**Year
                Ended**
              **December
                31, 2005**
            
            **Year
                Ended**
              **December
                31, 2004**Revenues
            
            
            100.00
            %
            
            100.00
            %Cost
                of revenues
            
            
            (93.56
            %)
            
            (90.17
            %)Gross
                margin
            
            
            6.44
            %
            
            9.83
            %Selling
                and distribution expenses
            
            
            (5.57
            %)
            
            (1.68
            %)General
                and administrative expenses
            
            
            (12.40
            %)
            
            (16.76
            %)Stock
                bonuses
            
            
            (22.92
            %)
            
            -
                -Depreciation
                and amortization
            
            
            (3.51
            %)
            
            (0.36
            %)Equity
                in loss of affiliate
            
            
            (0.00
            %)
            
            (0.00
            %)Goodwill
                written off
            
            
            (0.11
            %)
            
            -
                -Interest
              income
            
            
            1.48
            %
            
            0.05
            %Interest
                expense
            
            
            (0.06
            %)
            
            -
                -Other
                income, net
            
            
            (1.73
            %)
            
            0.03
            %Income
                tax expense
            
            
            (0.01
            %)
            
            (0.30
            %)Minority
                interest
            
            
            0.73
            %
            
            0.34
            %Net
                Loss
            
            
            (34.09
            %)
            
            (8.86
            %)







**YEAR
      ENDED DECEMBER 31, 2005 COMPARED TO YEAR ENDED DECEMBER 31,
      2004**




Revenues,
      Cost of Revenues and Gross Margin





Revenues
      for the year ended December 31, 2005 were $2,443,060, a decrease of $35,703
      from
      $2,478,763 in 2004. Our decrease in sales revenues in 2005 were mainly
      attributable to the decrease in our sales in pharmaceutical raw materials in
      2005 against 2004, offset by an increase in sales in plant extracts and
      pharmaceutical intermediates in 2005 compared to 2004:









For
                  the year ended December 31,Product
              
              2005
              
              2004
              
              Increase/
                (Decrease)Pharmaceutical
                  raw materials
              
              $
              1,941,036
              
              $
              2,326,960
              
              $
              (385,924
              )Plant
                  extracts
              
              
              68,932
              
              
              6,955
              
              
              61,977Pharmaceutical
                  intermediates
              
              
              433,092
              
              
              144,848
              
              
              288,244TOTAL
              
              $
              2,443,060
              
              $
              2,478,763
              
              $
              (35,703
              )
  Our
        decrease in sales of pharmaceutical raw materials in 2005 was mainly due
        to a
        decrease in our sales of Rutin NF11, one of our major products in the category
        of pharmaceutical raw materials. The sales of plant extracts increased in
        2005
        as compared to 2004 due to an increase in our export sales of Ginkgo Biloba
        Extracts. Our increase in sales of pharmaceutical intermediates in 2005 was
        mainly due to increase of our export sales of Rutin DAB9 and Rutin DAB10,
        our
        major products in the category of pharmaceutical
        intermediates.





Cost
      of
      revenues for the year ended December 31, 2005 were $2,285,628, an increase
      of
      $50,439 from $2,235,189 as compared to 2004. Compared to 2004, the increase
      in
      cost of sales of our products was because of the change in costs in the
      following product categories:




For
                  the year ended December 31,Product
              
              2005
              
              2004
              
              Increase/(Decrease)Pharmaceutical
                  raw materials
              $
              1,816,376
              $
              2,102,493
              $
              (286,117)Plant
                  extracts
              
              56,351
              
              5,949
              
              50,402Pharmaceutical
                  intermediates
              
              412,901
              
              126,747
              
              286,154TOTAL
              $
              2,285,628
              $
              2,235,189
              $
              50,439
  Our
        overall profit margin decreased from 10% in 2004 to 6% in 2005. Our profit
        margin for pharmaceutical raw materials and pharmaceutical intermediates
        decreased from 10% in 2004 to 6% in 2005 and from 12% in 2004 to 5% in 2005,
        respectively. The decrease in our profit margin of pharmaceutical raw materials
        was mainly due to an increase in the cost of our raw materials in the production
        process. Pharmaceutical intermediates decreased in profit margin due to a
        decrease in our profit margins in export sales of Rutin DAB9 and Rutin DAB10,
        which were the two products with the highest profit margin in 2004. Our profit
        margin for plant extracts, however, increased from 14% in 2004 to 18% in
        2005 as
        a result of increase in export sales of Ginkgo Biloba Extracts, which was
        higher
        in profit margin as compared to the rest of the products in the category
        of
        plant extracts.





Gross
      margin for the year ended December 31, 2005 was $157,432, a decrease of $86,142
      from $243,574 from 2004.





General
      and Administrative Expenses





General
      and Administrative expenses totaled to $302,982 for the year ended December
      31,
      2005, a decrease of $112,360 from $415,342 in 2004. The decrease in general
      and
      administrative expenses was mainly due to changes in the following
      expenses:




1.
              Increase
                  in payroll expenses of $7,093
              :
              As
                  a result of increase in number of employees in technical department
                  from 7
                  to 9.2.
              Increase
                  in travel expenses of $1,920
              :
              As
                  a result of increase in traveling of our executives for business
                  meetings.3.
              Decrease
                  in professional expenses of $89,623
              :
              We
                  incurred professional fees during 2004 for several one off services
                  related to our listing on OTC BB market. In 2005 these one off
                  expenses
                  were not repeated and our professional fees were
                  reduced.4.
              Decrease
                  in miscellaneous expenses of $31,750
              :
              In
                  2005 we reduced our miscellaneous general and administrative expenses
                  of
                  $31,750 as a result of our cost reduction initiatives.









Selling
      and Distribution Expenses





Selling
      and distribution expenses amounted to $136,062 for the year ended December
      31,
      2005, an increase of $94,493 from $41,569 in 2004. The increases in our selling
      and distribution expenses in 2005 compared to 2004 were mainly due to the
      followings:





1.
            Increase
                in payroll expenses of $12,176
            :
            As
                a result of increase in number of employees in sales department from
                13 to
                16.2.
            Increase
                in transportation expenses of $19,080
            :
            As
                a result of increase in traveling of our sales executives for export
                trading and sales meetings3.
            Increase
                in entertainment, meal and accommodation expenses of
                $30,228
            :
            As
                a result of increase in entertainment, meal and accommodation expenses
                in
                associated of increase in traveling overseas4.
            Increase
                in export insurance premiums of $5,685
            :
            As
                a result of our increase in export sales5.
            Increase
                in speed courier expenses of $2,580
            :
            As
                a result of our increase in demand of speed courier services for
                document
                and product samples in connection to increase in export
                sales6.
            Increase
                in other expenses of $24,744
            
            As
                a result of increase in sales and marketing staffs and increased
                sales and
                marketing activities





Liquidity
      and Capital Resources




Cash




Our
      cash
      balance amounted to $89,108 at December 31, 2005.




In
      the
      year ended December 31, 2005, our cash used in operating activities amounted
      to
      $357,005, mainly due to the net loss in the current year of $832,767. Also,
      in
      the current year, our accounts receivable increased by $1,062,930 as a result
      of
      an increase in export sales that usually had a longer accounts receivable cycle.
      Our inventories, however, were reduced by $376,244 due to our effort in reducing
      our inventories reserves. In the year ended December 31, 2005, cash used in
      investing activities amounted to $2,212,423. This was mainly due to the fact
      that we used $1,810,445 cash to purchase property and equipment in 2005. Cash
      flow from financing activities amounted to $2,415,458represent contribution
      from
      shareholders.




The
      Company is currently funding its operations from and in addition to sales
      revenues.




Working
      Capital




Our
      working capital amounted to $2,581,960 at December 31, 2005.









**NEW
      ACCOUNTING PRONOUNCEMENTS**




In
      December 2004, the Financial Accounting Standards Board (“FASB”) issued a
      revised SFAS No. 123, Accounting for Stock-Based Compensation, which supersedes
      APB opinion No. 25, Accounting for Stock Issued to Employees, and its related
      implementation guidance. This statement requires a public entity to recognize
      and measure the cost of employee services it receives in exchange for an award
      of equity instruments based on the grant-date fair value of the award (with
      limited exceptions). These costs will be recognized over the period during
      which
      an employee is required to provide service in exchange for the award - the
      requisite service period (usually the vesting period). This statement also
      establishes the standards for the accounting treatment of these share-based
      payment transactions in which an entity exchanges its equity instruments for
      goods or services. It addresses transactions in which an entity incurs
      liabilities in exchange for goods or services that are based on the fair value
      of the entity's equity instruments or that may be settled by the issuance of
      those equity instruments. This statement shall be effective the first interim
      or
      annual reporting period that begins after December 15, 2005 for small business
      public entities and nonpublic companies.




We
      believe that the implementation of this new pronouncement will not have any
      affect on our 2006 consolidated financial statements.




**INFLATION**




Inflation
      has not had a material impact on our business.




**CURRENCY
      EXCHANGE FLUCTUATIONS**




All
      of
      Company's revenues and majority of the expenses in 200 5
      were
      denominated primarily in Renminbi ("RMB"), the currency of China, and was
      converted into US dollars at the exchange rate of 8.3 to 1. On July 22, 2005,
      Renminbi rose about 2 percent against the US dollar at the exchange rate of
      8.11
      to 1. As a result of the appreciation of RMB we recognized a foreign currency
      translation gain of $75,567. There could be no assurance that RMB-to-U.S. dollar
      exchange rates will remain stable. A devaluation of RMB relative to the U.S.
      dollar would adversely affect our business, financial condition and results
      of
      operations. We do not engage in currency hedging.




**ITEM
      7**  **FINANCIAL
      STATEMENTS**




The
      financial statements, together with the independent auditors' report thereon,
      appears beginning on page F-1 of this report




**ITEM
      8**  **CHANGES
      IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL
      DISCLOSURES**




On
      March
      14, 2005, the accounting firm of Jimmy C. H. Cheung & Co., Certified Public
      Accountants (a member of Kreston International), 304 Dominion Centre, 43 Queen's
      Road East, Hong Kong, was engaged to take over the audit responsibilities from
      Epstein Weber & Conover, PLC, Certified Public Accountants; and Epstein
      Weber & Conover, PLC was dismissed on that same date.




During
      our two most recent fiscal years and any subsequent interim period prior to
      the
      engagement of Jimmy C. H. Cheung & Co., Certified Public Accountants, we has
      not consulted with Jimmy C. H. Cheung & Co., Certified Public Accountants,
      or any other auditor, regarding any accounting or audit concerns, to include,
      but not by way of limitation, those stated in Item 304(a)(2) of Regulation
      S-B.




During
      our two most recent fiscal years and the subsequent interim period through
      the
      date of dismissal, we are not aware of any disagreements with its former
      accountants, whether resolved or not resolved, on any matter of accounting
      principals or practices, financial statement disclosure, or auditing scope
      or
      procedure, which, if not resolved to said accountants' satisfaction, would
      have
      caused it to make reference to the subject matter of the disagreements(s) in
      connection with its report.









**ITEM
      8A**  **CONTROLS
      AND PROCEDURES**




We
      maintain disclosure controls and procedures that are designed to ensure that
      information required to be disclosed in the Company's Exchange Act reports
      is
      recorded, processed, summarized and reported within the time periods specified
      in the SEC's rules and forms, and that such information is accumulated and
      communicated to our management, including its Chief Executive Officer and Chief
      Financial Officer, as appropriate, to allow timely decisions regarding required
      disclosure based closely on the definition of "disclosure controls and
      procedures" in Rule 13a-14(c). Our disclosure controls and procedures are
      designed to provide a reasonable level of assurance of reaching our desired
      disclosure control objectives. In designing and evaluating the disclosure
      controls and procedures, our management recognized that any controls and
      procedures, no matter how well designed and operated, can provide only
      reasonable assurance of achieving the desired control objectives, and management
      necessarily was required to apply its judgment in evaluating the cost-benefit
      relationship of possible controls and procedures. Our certifying officers have
      concluded that our disclosure controls and procedures are effective in reaching
      that level of assurance.




As
      of the
      end of the period of this report, wecarried out an evaluation, under the
      supervision and with the participation of our management including our Chief
      Executive Officer and our Chief Financial Officer, of the effectiveness of
      the
      design and operation of our disclosure controls and procedures. Based on the
      foregoing, our Chief Executive Officer and Chief Financial Officer concluded
      that our disclosure controls and procedures were effective.




**ITEM
      8B OTHER INFORMATION**




Not
      applicable.




**PART
      III**




**ITEM
      9**  **DIRECTORS,
      EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS, COMPLIANCE WITH SECTION
      16(A)
      OF THE EXCHANGE ACT**




The
      following table sets forth the names and ages of our current directors and
      executive officers, their principal offices and positions and the date each
      such
      person became a director or executive officer of our company. Our executive
      officers are elected annually by the Board of Directors. Our directors serve
      one
      year terms until their successors are elected. The executive officers serve
      terms of one year or until their death, resignation or removal by the Board
      of
      Directors. There are no family relationships between any of the directors and
      executive officers. In addition, there were no arrangements or understanding
      between any executive officer and any other person pursuant to which any person
      was selected as an executive officer. Currently,
      directors are not compensated for serving on the Board of Directors. We have
      not
      established compensation or executive committees. Currently, our entire board
      of
      directors serves as our audit committee. Because of the small size of the
      Company and the risk attendant to a small public company, we are currently
      unable to attract an audit committee financial expert to our Board of Directors.





**BIOGRAPHIES
      OF OFFICERS AND DIRECTORS**




Jingan
      Wang




Mr.
      Jingan Wang, age 45, Chief Executive Officer of the Company, is the founder
      and
      currently serves as President of Huifeng. Mr. Wang has over fifteen years of
      experience in accounting and financial management area. Mr. Wang has served
      as
      Accounting Supervisors and Chief Financial Officers for various companies during
      his professional career. Before Mr. Wang founded Huifeng in 2000, he was the
      Chief Financial Officer for Wei Xing Enterprises from 1999 to 2000. In 2004,
      he
      was awarded "the Entrepreneur of the Year" by the Xian Hi Tech Development
      Zone.
      Mr. Wang is also a certified public accountant.




Sanding
      Tao




Mr.
      Sanding Tao, age 37, Chief Financial Officer of the Company and of Huifeng.
      Mr.
      Tao served as VP of Finance and CFO for various technology and bio-tech firms
      before he joined Huifeng in 2003. From 1998 - 2000, Mr. Tao served as Chief
      Financial Officer for Xian Lan Xi Science & Technology Inc.; and from 2000
      -2003, Mr. Tao served as Chief Financial Officer for Xian Xing Yi Science &
Technology Inc. Mr. Tao is a graduate of Chinese Southern Financial
      College.









Xinwen
      Hou




Mr.
      Xinwen Hou, age 37,Director and Secretary of the Company, currently also serves
      as Assistant to the President and as Company Secretary for Huifeng Biochemistry
      Joint Stock Company ("Huifeng") in Xian, China. Mr. Hou held various leadership
      positions in different public companies in China before he joined Huifeng in
      January 2004. From 1997 - 2003, Mr. Hou served as Company Secretary for De
      Li
      Bang Pharmaceutical Inc., which is listed on China's A share stock exchange.
      He
      is also a reputable economist. He graduated from Xian Transportation University
      with a major in Business Administration.




The
      following table summarizes the information of the directors and executive
      officers of our Company:




**Name**
              
              **Position**
              
              **Date
                  Of Appointment**Jingan
                  Wang
              
              Chief
                  Executive Officer
              
              December
                  20, 2004Sanding
                  Tao
              
              Chief
                  Financial Officer
              
              December
                  20, 2004Xinwen
                  Hou
              
              Director
                  and Secretary
              
              December
                  20, 2004
  **INDEMNIFICATION
        OF DIRECTORS AND OFFICERS**




Our
      articles of incorporation limit the liability of directors to the maximum extent
      permitted by Nevada law. This limitation of liability is subject to exceptions
      including intentional misconduct, obtaining an improper personal benefit and
      abdication or reckless disregard of director duties. Our articles of
      incorporation and bylaws provide that we may indemnify its directors, officer,
      employees and other agents to the fullest extent permitted by law. Our bylaws
      also permit us to secure insurance on behalf of any officer, director, employee
      or other agent for any liability arising out of his or her actions in such
      capacity, regardless of whether the bylaws would permit indemnification. We
      currently do not have such an insurance policy.




Insofar
      as indemnification for liabilities arising under the Securities Act of 1933
      may
      be permitted for our directors, officers and controlling 1934 persons pursuant
      to the foregoing provisions, or otherwise, we have been advised that in the
      opinion of the Securities and Exchange Commission such indemnification is
      against public policy as expressed in the Securities Act and is, therefore,
      unenforceable.




**CODE
      OF ETHICS**




We
      have
      adopted a Code of Ethics and Business Conduct authorizing the establishment
      of a
      committee to ensure that our disclosure controls and procedures remain
      effective.  Our Code also defines the standard of conduct expected by our
      officers, directors and employees.




**ITEM
      10.**  **EXECUTIVE
      COMPENSATION**




The
      executives of the Company received no compensation from the Company for the
      fiscal year ending December 31, 2004. The Company currently has no agreements
      for compensation of its executives, and has no stock option plan or other equity
      compensation plan for its employees.




**ITEM
      11.**  **SECURITY
      OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT**




The
      following table sets forth certain information regarding beneficial ownership of common stock as of March 30, 2006 by each person known to us to
      own
      beneficially more than 5% of our common stock, each of our directors, each
      of
      our named executive officers; and all executive officers and directors as a
      group.







Name
              Position
                  Held
              Shares
                  Owned
              %
                  OwnedJingan
                  Wang
              Chief
                  Executive Officer
              7,305,074
              46.63%Sanding
                  Tao
              Chief
                  Financial Officer
              325,442
              2.08%Xinwen
                  Hou
              Director
                  and Secretary
              325,442
              2.08%Xian
                  Renfeng Investment Ltd. Co.
              821,567
              5.24%**All
                  directors and executive officers as a group**
              **7,955,958**
              **50.79%**




**ITEM
      12.**  **CERTAIN
      RELATIONSHIPS AND RELATED TRANSACTION**




As
      of
      December 31, 2005 and 2004, the stockholders owed the Company $100,007 and
      $62,493 respectively for advances made on an unsecured basis and repayable
      on
      demand. Interest is charged at 6% per annum on the amount due. Total interest
      income amounted to $5,664 and $0 for the years ended December 31, 2005 and
      2004,
      respectively.





As
      of
      December 31, 2005 and 2004, the Company also owed the stockholders $1,239 and
      $193,433 respectively for advances made on an unsecured basis, free of interest
      payment and repayable on demand.





The
      Company issued a Convertible Promissory Note of $1,900,000 to the shareholders
      of Northwest; the Note was converted on October 12, 2005 into 10,465,725 (post
      a
      one for eighteen reverse split) shares to exchange for 70% of the outstanding
      shares of Northwest.




**ITEM
      13.**  **EXHIBITS**




3.1.
              Articles
                  of Incorporation (1)3.2
              By
                  Laws (1)3.3
              Certificate
                  of Amendment to Articles of Incorporation (2)10.1
              Stock
                  Purchase Agreement dated as of December 20, 2004 by and among Art
                  Malone,
                  Jr., Zhi Lan Wang and Jun Lin(3)10.2
              Agreement
                  and Plan of Reorganization dated as of December 20, 2004 by and
                  among
                  Secured Data, Inc., Northwest Bio-Technic Inc., and the shareholders
                  of
                  Northwest Bio- Technic Inc.; and Convertible Promissory Note
                  (3)10.3
              Amendment
                  No. 1 to the Convertible Promissory Note Due June 30, 2005
                  (4)23.1
              Consent
                  of Jimmy C.H. Cheung & Co., Certified Public
                  Accountants31.1
              Sarbanes
                  Oxley Section 302 Certification of Chief Executive
                  Officer31.2
              Sarbanes
                  Oxley Section 302 Certification of Chief Financial
                  Officer32.1
              Sarbanes
                  Oxley Section 906 Certification of Chief Executive
                  Officer32.2
              Sarbanes
                  Oxley Section 906 Certification of Chief Financial
                  Officer99.1
              Code
                  of Ethics (2)





(1)
      Incorporated by reference from the Registration Statement on Form SB-2 filed
      on or
      about
      July 28, 2000 .


(2)
      Incorporated by reference from the Annual Report on Form 10-K filed on or about
      June 20, 2005.


(3)
      Incorporated by reference from the Current Report on Form 8-K filed on or
      about
      December 27, 2004.


(4)
      Incorporated by reference from the Current Report on Form 8-K filed on or about
      July 7, 2005.




**ITEM
      14. PRINCIPAL ACCOUNTING FEES AND SERVICES**




**AUDIT
      FEES**




The
      aggregate fees billed for each of the last two fiscal years for professional
      services rendered by the principal accountant for our audit of annual financial
      statements and review of financial statements included in our Form 10-KSBs
      and
      10-QSBs for services that are normally provided by the accountant in connection
      with statutory and regulatory filings or engagements for those fiscal years
      was:













2005:
      $60,000   -
      Jimmy
      C.H. Cheung & Co.




2004:
      $40,000   -
      Jimmy
      C. H. Cheung & Co.




**AUDIT-RELATED
      FEES**





For
      fiscal 2005 and 2004, the Company's auditors did not bill any fees for assurance
      and related services that are reasonably related to the performance of the
      audit
      or review of the Company's financial statements and are not reported under
      "Audit Fees" above.





**TAX
      FEES**





No
      fees
      were billed by the Company's auditors for professional services for tax
      compliance, tax advice, and tax planning for fiscal 2005 and 2004, respectively.





**ALL
      OTHER FEES**




The
      aggregate fees billed in each of the last two fiscal years for the products
      and
      services provided by the principal accountant, other than the services reported
      in paragraph (1) was:




2005
      and
      2004: $0   -
      Jimmy
      C. H. Cheung & Co.




**AUDIT
      COMMITTEE**





The
      Company’s Board of Directors acts as its audit committee, and it meets prior to
      filing of any Form 10-QSB or 10-KSB to approve those filings. In addition,
      the
      committee meets to discuss audit plans and anticipated fees for audit and tax
      work prior to the commencement of that work. Approximately 100% of all fees
      paid
      to our independent auditors for fiscal 2005 are pre-approved by the audit
      committee.









**SIGNATURES**




Pursuant
      to the requirements of Section 13 or 15(d) of the Securities and Exchange Act,
      the Registrant has duly caused this Report to be signed on its behalf by the
      undersigned thereunto duly authorized.




Date: March
              28, 2006
            By:
            /s/ Jingan
              WangChief
                Executive Officer




Pursuant
      to the requirements of the Securities and Exchange Act of 1934, this Report
      has
      been signed below by the following person on behalf of the Registrant and in
      the
      capacities and on the dates indicated.




SIGNATURE
            TITLE
            DATE/s/ Jingan
              Wang
            Chairman
                and Chief Executive Officer (Principal Executive Officer)
            March
                28, 2006


/s/ Sanding
              Tao
            Chief
                Financial Officer (Principal Financial Officer)
            March
                28, 2006


/s/ Xinwen
              Hou
            Secretary,
                Director
            March
                28, 2006




HUIFENG
        BIO-PHARMACEUTICAL TECHNOLOGY INC.
 (PREVIOUSLY
          SECURED DATA, INC.) AND SUBSIDIARIES
 
 CONSOLIDATED
          FINANCIAL STATEMENTS
 AS
          OF
          DECEMBER 31, 2005 AND 2004 (RESTATED)
  
  HUIFENG
          BIO-PHARMACEUTICAL TECHNOLOGY INC.
 (PREVIOUSLY
          SECURED DATA, INC.) AND SUBSIDIARIES
 
 CONTENTS
 
 **Pages**Report
                    of Independent Registered Public Accounting Firm
                  
                  1Consolidated
                    Balance Sheets as of December 31, 2005 and 2004
                    (Restated)
                  
                  2Consolidated
                      Statements of Operations and Comprehensive loss for the years
                      ended
                      December 31, 2005and
                      2004 (Restated)
                  
                  3Consolidated
                      Statements of Stockholders’ Equity for the years ended December 31, 2005
                      and 2004(Restated)
                  
                  4Consolidated
                      Statements of Cash Flows for the years ended December 31, 2005
                      and 2004
                      (Restated)
                  
                  5Notes
                      to Consolidated Financial Statements as of December 31, 2005
                      and 2004
                      (Restated)
                  
                  6
                    -
                    19
  
   [Missing Graphic Reference]
                **Jimmy
                    C.H. Cheung & Co**
                  *Certified
                    Public Accountants*
                  *(A
                    member of Kreston International)*
                Registered
                    with the Public Company Accounting Oversight
                    Board
   **REPORT
          OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM** ****
 
 To
          the
          Board of Directors of:
 Huifeng
          Bio-pharmaceutical Technology Inc.
 (Previously
          Secured Data, Inc.) and Subsidiaries
 
 We
          have
          audited the accompanying consolidated balance sheets of Huifeng
          Bio-pharmaceutical Technology Inc. (previously Secured Data, Inc.) and
          subsidiaries as of December 31, 2005 and 2004 (restated) and the related
          consolidated statements of operations and comprehensive loss, changes in
          stockholders’ equity and cash flows for the
          years
          ended December 31, 2005 and 200 4
          (restated). These financial statements are the responsibility of the Company’s
          management. Our responsibility is to express an opinion on these financial
          statements based on our audits.
 
 We
          conducted our audits in accordance with the standards of the Public Company
          Accounting Oversight Board (United States). Those standards require that
          we plan
          and perform the audits to obtain reasonable assurance about whether the
          financial statements are free of material misstatement. An audit includes
          examining, on a test basis, evidence supporting the amounts and disclosures
          in
          the financial statements. An audit also includes assessing the accounting
          principles used and significant estimates made by management, as well as
          evaluating the overall financial statement presentation. We believe that
          our
          audits of the financial statements provide a reasonable basis for our opinion.
 
 In
          our
          opinion, the financial statements referred to above present fairly, in
          all
          material respects, the financial position of Huifeng Bio-pharmaceutical
          Technology Inc. (previously Secured Data, Inc.) and subsidiaries, as of
          December
          31, 2005 and 2004 (restated), and the consolidated results of its operations
          and
          its cash flows for the years ended December 31, 2005 and 2004 (restated),
          in
          conformity with accounting principles generally accepted in the United
          States of
          America.
 
 As
          discussed in Note 2, the accompanying consolidated financial statements
          for the
          year ended December 31, 2004 have been restated.
  **JIMMY
          C.H. CHEUNG & CO**
 Certified
          Public Accountants
  Hong
          Kong
  Date:
          February 18, 2006 except for Note 20, which the date is March 28,
          2006.
 
  
 1607
          Dominion Centre, 43 Queen’s Road East, Wanchai, Hong Kong
 Tel:
          (852) 25295500 Fax: (852) 28651067 Email:
          jchc@krestoninternational.com.hk
 Website:
          http://www.jimmycheungco.com
  1
  HUIFENG
          BIO-PHARMACEUTICAL TECHNOLOGY INC.
 (PREVIOUSLY
          SECURED DATA, INC.) AND SUBSIDIARIES
 CONSOLIDATED
          BALANCE SHEETS
 AS
          OF
          DECEMBER 31, 2005 AND 2004 (RESTATED)
 
 **ASSETS**
                  
                  
                  
                  2005
                  
                  2004(As
                      restated)**CURRENT
                      ASSETS**Cash
                      and cash equivalents
                  
                  
                  
                  
                  $
                  89,108
                  
                  $
                  167,511Accounts
                      receivable, net of allowances
                  
                  
                  
                  
                  
                  1,136,558
                  
                  
                  104,144Inventories,
                      net
                  
                  
                  
                  
                  
                  925,781
                  
                  
                  1,302,025Loans
                      receivable
                  
                  
                  
                  
                  
                  433,168
                  
                  
                  -Due
                      from stockholders
                  
                  
                  
                  
                  
                  100,071
                  
                  
                  62,493Other
                      assets
                  
                  
                  
                  
                  
                  291,811
                  
                  
                  335,058Total
                      Current Assets
                  
                  
                  
                  
                  
                  2,976,497
                  
                  
                  1,971,231**PROPERTY
                      AND EQUIPMENT, NET**
                  
                  
                  
                  
                  
                  2,524,243
                  
                  
                  879,503**LAND
                      USE RIGHTS, NET**
                  
                  
                  
                  
                  
                  131,227
                  
                  
                  133,974**OTHER
                      ASSETS**Investment
                      in affiliate
                  
                  
                  
                  
                  
                  -
                  
                  
                  31,190**TOTAL
                      ASSETS**
                  
                  
                  
                  
                  $
                  5,631,967
                  
                  $
                  3,015,898**LIABILITIES
                      AND STOCKHOLDERS' EQUITY****CURRENT
                      LIABILITIES**Accounts
                      payable
                  
                  
                  
                  
                  $
                  163,872
                  
                  $
                  56,454Other
                      payables and accrued expenses
                  
                  
                  
                  
                  
                  156,765
                  
                  
                  145,191Value
                      added tax payables
                  
                  
                  
                  
                  
                  92,281
                  
                  
                  12,323Income
                      tax and other tax payables
                  
                  
                  
                  
                  
                  380
                  
                  
                  6,684Convertible
                      note payable
                  
                  
                  
                  
                  
                  -
                  
                  
                  1,900,000Due
                      to stockholders
                  
                  
                  
                  
                  
                  1,239
                  
                  
                  193,433Total
                      Current Liabilities
                  
                  
                  
                  
                  
                  414,537
                  
                  
                  2,314,085**COMMITMENTS
                      AND CONTINGENCIES**
                  
                  
                  
                  
                  
                  -
                  
                  
                  -**MINORITY
                      INTEREST**
                  
                  
                  
                  
                  
                  456,274
                  
                  
                  58,915**STOCKHOLDERS'
                      EQUITY**Preferred
                      stock ($0.001 par value, 5,000,000 shares
                      authorized,none
                      issued and outstanding)
                  
                  
                  
                  
                  
                  -
                  
                  
                  -Common
                      stock ($0.018 par value, 100,000,000 shares authorized,16,466,169
                      shares issued and outstanding as ofDecember
                      31, 2005; issued and outsanding 5,200,444 sharesas
                      of December 31, 2004)
                  
                  
                  
                  
                  
                  295,391
                  
                  
                  93,608Additional
                      paid-in capital
                  
                  
                  
                  
                  
                  7,256,0636
                  
                  
                  2,583,388Retained
                      earnings (deficit)Unappropriated
                  
                  
                  
                  
                  
                  (2,890,139
                  )
                  
                  (2,041,348
                  )Appropriated
                  
                  
                  
                  
                  
                  23,274
                  
                  
                  7,250Accumulated
                      other comprehensive income
                  
                  
                  
                  
                  
                  75,567
                  
                  
                  -Total
                      Stockholders' Equity
                  
                  
                  
                  
                  
                  4,761,156
                  
                  
                  642,898**TOTAL
                      LIABILITIES AND STOCKHOLDERS' EQUITY**
                  
                  
                  
                  
                  $
                  5,631,967
                  
                  $
                  3,015,898
 The
            accompanying notes are an integral part of these financial
            statements
 2
  HUIFENG
          BIO-PHARMACEUTICAL TECHNOLOGY INC.
 (PREVIOUSLY
          SECURED DATA, INC.) AND SUBSIDIARIES
 CONSOLIDATED
          STATEMENTS OF OPERATIONS
 AND
          COMPREHENSIVE LOSS
 FOR
          THE YEARS ENDED DECEMBER 31, 2005 AND 2004 (RESTATED)
 
 
 20042005
                  
                  (As
                      restated)**NET
                      SALES**
                  
                  $
                  2,443,060
                  
                  $
                  2,478,763**COST
                      OF SALES**
                  
                  
                  (2,285,628
                  )
                  
                  (2,235,189
                  )**GROSS
                      PROFIT**
                  
                  
                  157,432
                  
                  
                  243,574**OPERATING
                      EXPENSES**Selling
                      expenses and distribution expenses
                  
                  
                  136,062
                  
                  
                  41,569General
                      and administrative expenses
                  
                  
                  302,982
                  
                  
                  415,342Stock
                      bonuses
                  
                  
                  560,000
                  
                  
                  -Goodwill
                      written off
                  
                  
                  2,764
                  
                  
                  -Depreciation
                      and amortization
                  
                  
                  85,698
                  
                  
                  9,012Total
                      Operating Expenses
                  
                  
                  1,087,506
                  
                  
                  465,923**LOSS
                      FROM OPERATIONS**
                  
                  
                  (930,074
                  )
                  
                  (222,349
                  )**OTHER
                      INCOME (EXPENSES)**Equity
                      in loss of affiliate
                  
                  
                  (112
                  )
                  
                  (211
                  )Interest
                      income
                  
                  
                  36,047
                  
                  
                  1,260Interest
                      expense
                  
                  
                  1,625
                  
                  
                  -Other
                      income
                  
                  
                  42,270
                  
                  
                  711Total
                      Other Income
                  
                  
                  79,830
                  
                  
                  1,760**LOSS
                      FROM OPERATIONS BEFORE TAXES AND MINORITY
                      INTEREST**
                  
                  
                  (850,244
                  )
                  
                  (220,589
                  )**INCOME
                      TAX EXPENSE**
                  
                  
                  (253
                  )
                  
                  (7,503
                  )**MINORITY
                      INTEREST**
                  
                  
                  17,730
                  
                  
                  8,362**NET
                      LOSS**
                  
                  
                  (832,767
                  )
                  
                  (219,730
                  )**OTHER
                      COMPREHENSIVE INCOME**Foreign
                      currency translation income
                  
                  
                  75,567
                  
                  
                  -**COMPREHENSIVE
                      LOSS**
                  
                  $
                  (757,200
                  )
                  $
                  (219,730
                  )**Net
                      loss per share-basic and diluted**
                  
                  $
                  (0.111
                  )
                  $
                  (0.049
                  )Weighted
                      average number of shares outstanding during the year-basic
                      and diluted
                  
                  
                  7,529,550
                  
                  
                  4,506,870
  The
          accompanying notes are an integral part of these financial
          statements
  3
  HUIFENG
          BIO-PHARMACEUTICAL TECHNOLOGY INC.
 (PREVIOUSLY
          SECURED DATA, INC.) AND SUBSIDIARIES
 CONSOLIDATED
          STATEMENTS OF STOCKHOLDERS’ EQUITY
 FOR
          THE YEARS ENDED DECEMBER 31, 2005 AND 2004 (RESTATED)
  Preferred
                        Stock
                    
                    Common
                        Stock
                    
                    Additionalpaid-in
                    
                    Unappropriatedretained
                    
                    Appropriatedretained
                    
                    Accumulatedother
                        comprehensive
                    
                    TotalShares
                    
                    Amount
                    
                    Shares
                    
                    Amount
                    
                    capital
                    
                    deficit
                    
                    earnings
                    
                    income
                    
                    (As
                        restated)Balance
                        at January 1, 2004
                    
                    
                    
                    
                    $
                    -
                    
                    
                    4,485,318
                    
                    $
                    80,736
                    
                    $
                    4,446,260
                    
                    $
                    (1,814,451
                    )
                    $
                    83
                    
                    $
                    -
                    
                    $
                    2,712,628Stock
                        issued in recapitalization
                    
                    
                    
                    
                    
                    -
                    
                    
                    715,126
                    
                    
                    12,869
                    
                    
                    (465,640
                    )
                    
                    (1,397,229
                    )
                    
                    -
                    
                    
                    -
                    
                    
                    (1,850,000
                    )Stock
                      issued for reverse split
                    
                    
                    
                    
                    
                    
                    
                    
                    166
                    
                    
                    3
                    
                    
                    (3
                    )Recapitalization
                    
                    
                    
                    
                    
                    -
                    
                    
                    -
                    
                    
                    -
                    
                    
                    (1,397,229
                    )
                    
                    1,397,229
                    
                    
                    -
                    
                    
                    -
                    
                    
                    -Net
                        loss for the year
                    
                    
                    
                    
                    
                    -
                    
                    
                    -
                    
                    
                    -
                    
                    
                    -
                    
                    
                    (219,730
                    )
                    
                    -
                    
                    
                    -
                    
                    
                    (219,730
                    )Transfer
                        to statutory and staffwelfare
                        reserves
                    
                    
                    
                    
                    
                    -
                    
                    
                    -
                    
                    
                    -
                    
                    
                    -
                    
                    
                    (7,167
                    )
                    
                    7,167
                    
                    
                    -
                    
                    
                    -Balance
                        at December 31, 2004
                    
                    
                    -
                    
                    
                    -
                    
                    
                    5,200,444
                    
                    
                    93,605
                    
                    
                    2,583,391
                    
                    
                    (2,041,348
                    )
                    
                    7,250
                    
                    
                    -
                    
                    
                    642,898Contribution
                        by stockholders
                    
                    
                    
                    
                    
                    -
                    
                    
                    -
                    
                    
                    -
                    
                    
                    2,415,458
                    
                    
                    -
                    
                    
                    -
                    
                    
                    -
                    
                    
                    2,415,458Stock
                        bonuses issued forconvertible
                        note
                    
                    
                    
                    
                    
                    -
                    
                    
                    10,465,725
                    
                    
                    188,383
                    
                    
                    1,711,617
                    
                    
                    -
                    
                    
                    -
                    
                    
                    -
                    
                    
                    1,900,000Stock
                        issued for services
                    
                    
                    
                    
                    
                    -
                    
                    
                    800,000
                    
                    
                    14,400
                    
                    
                    545,600
                    
                    
                    -
                    
                    
                    -
                    
                    
                    -
                    
                    
                    560,000Net
                        loss for the year
                    
                    
                    
                    
                    
                    -
                    
                    
                    -
                    
                    
                    -
                    
                    
                    -
                    
                    
                    (832,767
                    )
                    
                    -
                    
                    
                    -
                    
                    
                    (832,767
                    )Comprehensive
                        income
                    
                    
                    
                    
                    
                    -
                    
                    
                    -
                    
                    
                    -
                    
                    
                    -
                    
                    
                    -
                    
                    
                    -
                    
                    
                    75,567
                    
                    
                    75,567Transfer
                        to statutory and staffwelfare
                        reserves
                    
                    
                    
                    
                    
                    -
                    
                    
                    -
                    
                    
                    -
                    
                    
                    -
                    
                    
                    (16,024
                    )
                    
                    16,024
                    
                    
                    -
                    
                    
                    -Balance
                        at December 31, 2005
                    
                    
                    -
                    
                    $
                    -
                    
                    
                    16,466,169
                    
                    $
                    296,388
                    
                    $
                    7,256,066
                    
                    $
                    (2,890,139
                    )
                    $
                    23,274
                    
                    $
                    75,567
                    
                    $
                    4,761,156
  The
          accompanying notes are an integral part of these financial
          statements
  4
  HUIFENG
          BIO-PHARMACEUTICAL TECHNOLOGY INC.
 (PREVIOUSLY
          SECURED DATA, INC.) AND SUBSIDIARIES
 CONSOLIDATED
          STATEMENTS OF CASH FLOWS
 FOR
          THE YEARS ENDED DECEMBER 31, 2005 AND 2004 (RESTATED)
 20042005
                  
                  (As
                      restated)**CASH
                      FLOWS FROM OPERATING ACTIVITIES**Net
                      loss
                  
                  $
                  (832,767
                  )
                  $
                  (219,730
                  )Adjusted
                      to reconcile net loss to cash (used in)provided
                      by operating activities:Allowance
                      for doubtful accounts - accounts receivable
                  
                  
                  30,516
                  
                  
                  -Depreciation
                      and amortization - cost of sales
                  
                  
                  82,754
                  
                  
                  85,085Depreciation
                      and amortization
                  
                  
                  85,698
                  
                  
                  9,012Equity
                      in loss of affiliate
                  
                  
                  -
                  
                  
                  211Minority
                      interest
                  
                  
                  397,359
                  
                  
                  (8,362
                  )Stock
                      issued for services
                  
                  
                  560,000
                  
                  
                  -Changes
                      in operating assets and liabilities(Increase)
                      decrease in:Accounts
                      receivable
                  
                  
                  (1,062,930
                  )
                  
                  122,023Inventories,
                      net
                  
                  
                  376,244
                  
                  
                  (405,019
                  )Due
                      from stockholders
                  
                  
                  (37,578
                  )
                  
                  569,717Other
                      assets
                  
                  
                  43,247
                  
                  
                  (236,920
                  )Increase
                      (decrease) in:Accounts
                      payable
                  
                  
                  107,418
                  
                  
                  7,194Other
                      payables and accrued expenses
                  
                  
                  11,574
                  
                  
                  101,234Value
                      added tax payables
                  
                  
                  79,958
                  
                  
                  12,323Income
                      tax and other taxes payable
                  
                  
                  (6,304
                  )
                  
                  6,586Due
                      to stockholders
                  
                  
                  (192,194
                  )
                  
                  184,354Net
                      cash (used in) provided by operating activities
                  
                  
                  (357,005
                  )
                  
                  227,708**CASH
                      FLOWS FROM INVESTING ACTIVITIES**Decrease
                      in notes receivable
                  
                  
                  -
                  
                  
                  506,774Increase
                      in loans receivable
                  
                  
                  (433,168
                  )
                  
                  -Decrease
                      in note payable
                  
                  
                  -
                  
                  
                  (241,642
                  )Purchase
                      of property and equipment
                  
                  
                  (1,810,445
                  )
                  
                  (305,070
                  )Decrease
                      (increase) in investment in affiliate
                  
                  
                  31,190
                  
                  
                  (31,401
                  )Acquisition
                      of land use rights
                  
                  
                  -
                  
                  
                  (134,661
                  )Net
                      cash used in investing activities
                  
                  
                  (2,212,423
                  )
                  
                  (206,000
                  )**CASH
                      FLOWS FROM FINANCING ACTIVITIES**Contribution
                      by the stockholders
                  
                  
                  2,415,458
                  
                  
                  50,000Net
                      cash provided by financing activities
                  
                  
                  2,415,458
                  
                  
                  50,000**EFFECT
                      OF EXCHANGE RATES ON CASH**
                  
                  
                  75,567
                  
                  
                  -**NET
                      (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS**
                  
                  
                  (78,403
                  )
                  
                  71,708**CASH
                      AND CASH EQUIVALENTS AT BEGINNING OF YEAR**
                  
                  
                  167,511
                  
                  
                  95,803**CASH
                      AND CASH EQUIVALENTS AT END OF YEAR**
                  
                  $
                  89,108
                  
                  $
                  167,511**SUPPLEMENTAL
                      DISCLOSURE OF CASH FLOW INFORMATION**Cash
                      paid during the year for:Income
                      taxes
                  
                  $
                  (7,225
                  )
                  $
                  (7,503
                  )Interest
                      expenses
                  
                  $
                  -
                  
                  $
                  -
  **SUPPLEMENTAL
          DISCLOSURE OF NON-CASH INVESTING AND FINANCING
          ACTIVITIES:**
 
 During
          2004, the Company issued 4,485,311 shares of common stock for 30% of the
          common
          stock of Northwest.
 
 During
          2004, the Company issued a Convertible Promissory Note of $1,900,000 for
          70% of
          the common stock of Northwest.
 
 On
          October 12, 2005, the Company issued 10,465,725 shares of restricted common
          stock to exercise the conversion of the Convertible Promissory Note of
          $1,900,000.
  The
          accompanying notes are an integral part of these
          financial statements
  5
  HUIFENG
          BIO-PHARMACEUTICAL TECHNOLOGY INC.
 (PREVIOUSLY
          SECURED DATA, INC.) AND SUBSIDIARIES
 NOTES
          TO
          THE CONSOLIDATED FINANCIAL STATEMENTS
 AS
          OF
          DECEMBER 31, 2005 AND 2004 (RESTATED)
 
 
 1.  **SUMMARY
          OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION**
 
 (A)  Organization
 
 Huifeng
          Bio-pharmaceutical Technology Inc. (previously Secured Data, Inc.) (“Huifeng
          Bio-pharmaceutical”) is a US listed company which was incorporated in Nevada on
          March 16, 2000 under the name Enternet, Inc. On May 23, 2002, the Articles
          of
          Incorporation were amended to change the name of the Company to Secured
          Data,
          Inc. On October 12, 2005, the Articles of Incorporation were amended to
          change
          the name of the Company to Huifeng Bio-pharmaceutical Technology
          Inc.
 
 Northwest
          Bio-Technic Inc. (“Northwest”) was incorporated in the British Virgin Islands
          (“BVI”) on June 25, 2004. Xian Huifeng Biochemistry Group Joint-Stock Company
          Limited (previously Xian Huifeng Biochemistry Joint-Stock Company Limited)
          (“Huifeng Biochemistry”) was incorporated in the People’s Republic of China
          (“PRC”) on January 20, 2000 as a company with limited liabilities and was
          restructured as a joint stock company on September 29, 2002 under the laws
          of
          the PRC. On April 20, 2005, the Articles of Incorporation were amended
          to change
          the name of Huifeng Biochemistry to Xian Huifeng Biochemistry Group Joint-Stock
          Company Limited.
 
 Huifeng
          Biochemistry produces plant extracts and bio-chemical products used as
          pharmaceutical raw materials in the PRC. Most of its products are distributed
          within the PRC and some European countries.
 
 On
          August
          23, 2001, Huifeng Biochemistry established a 70% owned subsidiary, Xian
          Huifeng
          Biochemistry Engineering Company Limited (“Huifeng Engineering”) in the PRC with
          a registered capital of $265,778. The subsidiary has no operations since
          its
          incorporation.
 
 On
          June
          16, 2004 Huifeng Biochemistry acquired an 86.7% interest in Baoji Jinsen
          Pharmaceutical Company Limited, later renamed to Xian Huifeng Pharmaceutical
          Company Limited (“Huifeng Pharmaceutical”), a limited liability company in the
          PRC. On November 10, 2004 Huifeng Pharmaceutical increased its registered
          capital from $181,159 to $603,865. The increased registered capital was
          fully
          subscribed by a stockholder of the Company, diluting the Company’s interest in
          Huifeng Pharmaceutical from 86.7% to 26%. On May 27, 2005 the PRC Government
          approved Huifeng Biochemistry’s increased investment in Huifeng Pharmaceutical
          from $31,401 to $1,685,990 through an increase in the registered capital
          of
          Huifeng Pharmaceutical from $603,865 to $2,258,454. The acquisition of
          Huifeng
          Pharmaceutical by Huifeng Biochemistry was through a step process increasing
          Huifeng Biochemistry’s interest in Huifeng Pharmaceutical from 26% to
          80.2%.
 
 During
          2004, Huifeng Biochemistry’s shareholders exchanged 100% of their ownership of
          Huifeng Biochemistry for 500,000 shares of Northwest under a reorganization
          plan. The transfer has been accounted for as a reorganization of entities
          under
          common control as the companies were beneficially owned by principally
          identical
          shareholders and share common management.
 
 On
          December 20, 2004, pursuant to a Stock Purchase Agreement, a Huifeng
          Bio-pharmaceutical shareholder sold 401,646 shares in Huifeng Bio-pharmaceutical
          to two Northwest shareholders for $300,000. On the same date, Huifeng
          Bio-pharmaceutical entered into an Agreement and Plan of Reorganization
          with the
          shareholders of Northwest to exchange 30% of Northwest’s outstanding shares for
          4,485,311 shares of Huifeng Bio-pharmaceutical. In addition, the Agreement
          calls
          for Huifeng Bio-pharmaceutical to issue a Convertible Promissory Note for
          $1,900,000 that is convertible into 10,465,725 (post a one for eighteen
          reverse
          split) shares of Huifeng Bio-pharmaceutical for the remaining 70% of Northwest.
          On October 12, 2005, the Company issued 10,465,725 shares of restricted
          common
          stock in conversion of the Convertible Promissory Note of
          $1,900,000.
 
 The
          merger of Huifeng Bio-pharmaceutical and Northwest has been recorded as
          a
          recapitalization by Northwest, with Northwest being treated as the continuing
          entity. The financial statements have been prepared as if the reorganization
          had
          occurred retroactively. Huifeng Bio-pharmaceutical, Northwest, Huifeng
          Biochemistry, Huifeng Engineering and Huifeng Pharmaceutical are hereafter
          referred to as (the “Company”).
  6
  HUIFENG
          BIO-PHARMACEUTICAL TECHNOLOGY INC.
 (PREVIOUSLY
          SECURED DATA, INC.) AND SUBSIDIARIES
 NOTES
          TO
          THE CONSOLIDATED FINANCIAL STATEMENTS
 AS
          OF
          DECEMBER 31, 2005 AND 2004 (RESTATED)
 
 
 1. **SUMMARY
          OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION**
 
 (A)
          Organization (continued)
 
 Accordingly,
          the financial statements include the following:
 
 (1)
                The
                    balance sheet consists of the net assets of the acquirer at historical
                    cost and the net assets of the acquiree at historical
                    cost.
 
 (2)
                The
                    statement of operations includes the operations of the acquirer
                    for the
                    periods presented and the operations of the acquiree from the
                    date of the
                    merger.
 
 (B)  Use
          of
          estimates
 
 The
          preparation of the financial statements in conformity with generally accepted
          accounting principles requires management to make estimates and assumptions
          that
          affect the reported amount of assets and liabilities and disclosure of
          contingent assets and liabilities at the date of the financial statements
          and
          the reported amounts of revenues and expenses during the reporting period.
          Actual results could differ from those estimates.
 
 (C)  Principles
          of consolidation
 
 The
          accompanying 2005 consolidated financial statements include the financial
          statements of Huifeng Bio-pharmaceutical and its 100% owned subsidiary
          Northwest, 100% owned subsidiary Huifeng Biochemistry, 70% owned subsidiary
          Huifeng Engineering and 80.2% owned subsidiary Huifeng Pharmaceutical from
          the
          date of its step acquisition on May 27, 2005 to December 31, 2005.
 
 The
          accompanying 2004 (restated) consolidated financial statements include
          the
          financial statements of Huifeng Bio-pharmaceutical and its 100% owned subsidiary
          Northwest, 100% owned subsidiary Huifeng Biochemistry, 70% owned subsidiary
          Huifeng Engineering and 86.7% owned subsidiary Huifeng Pharmaceutical from
          the
          date of its acquisition on June 16, 2004 to the date of its dilution in
          November
          11, 2004 to December 31, 2004 under the equity method accounting.
 
 All
          significant inter-company balances and transactions have been eliminated
          in
          consolidation.
 
 In
          October 2005, the Company effected a one for eighteen reverse stock split.
          All
          shares and per share information of common stock in the accompanying financial
          statements have been retroactively restated to reflect the effect of this
          stock
          split.
 
 (D)  Cash
          and
          cash equivalents
 
 For
          purpose of the statements of cash flows, cash and cash equivalents include
          cash
          on hand and demand deposits with a bank with a maturity of three months
          or
          less.
 
 (E)
                Accounts
                    receivable
 
 The
          Company extends unsecured credit to its customers in the ordinary course
          of
          business but mitigates the associated risks by performing credit checks
          and
          actively pursuing past due accounts. An allowance for doubtful accounts
          is
          established and recorded based on managements’ assessment of the credit history
          with the customer and current relationships with them. For the years ended
          December 31, 2005 and 2004, the Company recorded an allowance for doubtful
          accounts of $30,516 and $0 respectively.
 
 (F)
                Inventories
 
 Inventories
          are stated at the lower of cost or market value, cost being determined
          on a
          first in, first out method. The Company provides for inventory allowances
          based
          on excess and obsolete inventories determined principally by customer
          demand.
  7
 HUIFENG
          BIO-PHARMACEUTICAL TECHNOLOGY INC.
 (PREVIOUSLY
          SECURED DATA, INC.) AND SUBSIDIARIES
 NOTES
          TO
          THE CONSOLIDATED FINANCIAL STATEMENTS
 AS
          OF
          DECEMBER 31, 2005 AND 2004 (RESTATED)
 
 
 1. **SUMMARY
          OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION
          (CONTINUED)**
 
 (G)
                Property
                    and equipment
 
 Property
          and equipment are stated at cost, less accumulated depreciation. Expenditures
          for additions, major renewals and betterments are capitalized and expenditures
          for maintenance and repairs are charged to expense as incurred.
 
 Depreciation
          is provided on a straight-line basis, less estimated residual value over
          the
          assets’ estimated useful lives. The estimated useful lives are as
          follows:
  
 Plant
                    and machinery
                10
                    YearsMotor
                    vehicles
                10
                    YearsFurniture,
                    fixtures and equipment
                5
                  Years
  Land
          use
          rights are stated at cost, less accumulated amortization. The land use
          rights
          are amortized over the term of the relevant rights of 50 years from the
          date of
          acquisition.
  (H)
                  Long-lived
                      assets
 The
          Company accounts for long-lived assets under the Statements of Financial
          Accounting Standards Nos. 142 and 144 “Accounting for Goodwill and Other
          Intangible Assets” and “Accounting for Impairment or Disposal of Long-Lived
          Assets” (“SFAS No. 142 and 144”). In accordance with SFAS No. 142 and 144,
          long-lived assets, goodwill and certain identifiable intangible assets
          held and
          used by the Company are reviewed for impairment whenever events or changes
          in
          circumstances indicate that the carrying amount of an asset may not be
          recoverable. For purposes of evaluating the recoverability of long-lived
          assets,
          when undiscounted future cash flows will not be sufficient to recover an
          asset’s
          carrying amount, the asset is written down to its fair value.
 
 (I)
                Fair
                    value of financial instruments
 
 Statement
          of Financial Accounting Standards No. 107, "Disclosure About Fair Value
          of
          Financial Instruments," requires certain disclosures regarding the fair
          value of
          financial instruments. Fair value of financial instruments is made at a
          specific
          point in time, based on relevant information about financial markets and
          specific financial instruments. As these estimates are subjective in nature,
          involving uncertainties and matters of significant judgment, they cannot
          be
          determined with precision. Changes in assumptions can significantly affect
          estimated fair values.
 
 The
          carrying value of cash and cash equivalents, accounts receivable (trade
          and
          others), accounts payable (trade and related party) and accrued liabilities
          approximate their fair value because of the short-term nature of these
          instruments. The Company places its cash and cash equivalents with what
          it
          believes to be high credit quality financial institutions. The Company
          has a
          diversified customer base, most of which are in the PRC. The Company controls
          credit risk related to accounts receivable through credit approvals, credit
          limit and monitoring procedures. The Company routinely assesses the financial
          strength of its customers and, based upon factors surrounding the credit
          risk,
          establishes an allowance, if required, for uncollectible accounts and,
          as a
          consequence, believes that its accounts receivable credit risk exposure
          beyond
          such allowance is limited.
 
 The
          Company’s major operation is in the PRC, which may give rise to significant
          foreign currency risks from fluctuations and the degree of volatility of
          foreign
          exchange rates between the United States dollars (“US$”) and the Chinese
          Renminbi (“RMB”). On July 21, 2005, PRC let the RMB to fluctuate ending its
          decade-old valuation peg to the US$. The new RMB rate reflects an approximately
          2% increase in value against the US$. Historically, the PRC government
          has
          benchmarked the RMB exchange ratio against the US$, thereby mitigating
          the
          associated foreign currency exchange rate fluctuation risk. The Company
          does not
          believe that its foreign currency exchange rate fluctuation risk is significant,
          especially if the PRC government continues to benchmark the RMB against
          the
          US$.
  8
  HUIFENG
          BIO-PHARMACEUTICAL TECHNOLOGY INC.
 (PREVIOUSLY
          SECURED DATA, INC.) AND SUBSIDIARIES
 NOTES
          TO
          THE CONSOLIDATED FINANCIAL STATEMENTS
 AS
          OF
          DECEMBER 31, 2005 AND 2004 (RESTATED)
  1. **SUMMARY
          OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION
          (CONTINUED)**
 
 (J)
                Revenue
                    recognition
 
 The
          Company recognizes revenue upon delivery or shipment of the products, at
          which
          time title passes to the customer provided that: there are no uncertainties
          regarding customer acceptance; persuasive evidence of an arrangement exists;
          the
          sales price is fixed or determinable; and collectability is deemed
          probable.
 
 (K)
                Income
                    taxes
 
 The
          Company accounts for income taxes under the Statement of Financial Accounting
          Standards No. 109, “Accounting for Income Taxes” (“Statement 109”). Under
          Statement 109, deferred tax assets and liabilities are recognized fort
          the
          future tax consequences attributable to differences between the financial
          statement carrying amounts of existing assets and liabilities and their
          respective tax bases. Deferred tax assets and liabilities are measured
          using
          enacted tax rates expected to apply to taxable income in the years in which
          those temporary differences are expected to be recovered or settled. Under
          Statement 109, the effect on deferred tax assets and liabilities of a change
          in
          tax rates is recognized in income in the period that included the enactment
          date.
 
 (L)
                Foreign
                    currency translation
 
 The
          functional currency of the Company is the Chinese Renminbi (“RMB”). Foreign
          currency transactions during the year are translated to RMB at the approximate
          rates of exchange on the dates of transactions. Monetary assets and liabilities
          denominated in foreign currencies at the balance sheet date are translated
          at
          the approximate rates of exchange at that date. Non-monetary assets and
          liabilities are translated at the rates of exchange prevailing at the time
          the
          asset or liability was acquired. Exchange gains or losses are recorded
          in the
          statement operations.
 
 The
          financial statements are translated into United States dollars (“US$”) using the
          closing rate method. The balance sheet items are translated into US$ using
          the
          exchange rates at the respective balance sheet dates. The capital and various
          reserves are translated at historical exchange rates prevailing at the
          time of
          the transactions while income and expenses items are translated at the
          average
          exchange rate for the year. All exchange differences are recorded within
          equity.
 
 The
          translation income recorded for the years ended December 31, 2005 and 2004
          was
          $75,567 and $0 respectively.
 
 (M)
                Comprehensive
                    loss
 
 The
          foreign currency translation gain or loss resulting from translation of
          the
          financial statements expressed in RMB to United States Dollar is reported
          as
          other comprehensive income in the statements of operations and stockholders’
equity. The foreign currency translation gain for the years ended December
          31,
          2005 and 2004 was $75,567 and $0 respectively.
 
 (N)
                Loss
                    per share
 
 Basic
          loss per share is computed by dividing loss available to common shareholders
          by
          the weighted average number of common shares outstanding during the period.
          Diluted income per share is computed similar to basic loss per share except
          that
          the denominator is increased to include the number of additional common
          shares
          that would have been outstanding if the potential common shares had been
          issued
          and if the additional common shares were dilutive.
 
 (O)
                Segments
 
 The
          Company operates in only one segment, thereafter segment disclosure is
          not
          presented.
  9
  HUIFENG
          BIO-PHARMACEUTICAL TECHNOLOGY INC.
 (PREVIOUSLY
          SECURED DATA, INC.) AND SUBSIDIARIES
 NOTES
          TO
          THE CONSOLIDATED FINANCIAL STATEMENTS
 AS
          OF
          DECEMBER 31, 2005 AND 2004 (RESTATED)
 
 
 1. **SUMMARY
          OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION
          (CONTINUED)**
 
 (P)  Recent
          Accounting Pronouncements
 
 In
          December 2004, the FASB issued SFAS No. 123R “Share-Based Payment”
(“SFAS 123R”), a revision to SFAS No. 123 “Accounting for Stock-Based
          Compensation” (“SFAS 123”), and superseding APB Opinion No. 25 “Accounting for
          Stock Issued to Employees” and its related implementation guidance. SFAS 123R
          establishes standards for the accounting for transactions in which an entity
          exchanges its equity instruments for goods or services, including obtaining
          employee services in share-based payment transactions. SFAS 123R applies
          to all
          awards granted after the required effective date and to awards modified,
          repurchased, or cancelled after that date. Adoption of the provisions of
          SFAS
          123R is effective as of the beginning of the first interim or annual reporting
          period that begins after June 15, 2005. The Company does not expect the
          adoption
          of this statement will have any material impact on its results or financial
          position.
 
 In
          November 2004, the FASB issued SFAS No. 151, "Inventory Costs -- an amendment
          of
          ARB No. 43, Chapter 4"(“SFAS 151”) This statement clarifies the criteria of
          "abnormal amounts" of freight, handling costs, and spoilage that are required
          to
          be expensed as current period charges rather than deferred in inventory.
          In
          addition, this statement requires that allocation of fixed production overheads
          to the costs of conversion be based on the normal capacity of the production
          facilities. SFAS 151 is effective for the Company July 1, 2005. The Company
          does
          not expect the adoption of this statement will have any material impact
          on its
          results or financial position.
 
 In
          December 2004, the FASB issued SFAS no. 153, *Exchanges
          of Nonmonetary Assets an amendment of APB Opinion No. 29.* This
          Statement addresses the measurement of exchanges of nonmonetary assets.
          It
          eliminates the exception from fair value measurement for nonmonetary exchanges
          of similar productive assets in paragraph 21(b) of APB Opinion No. 29, *Accounting
          for Nonmonetary Transactions,* and
          replaces it with an exception for exchanges that do not have commercial
          substance. This Statement specifies that a nonmonetary exchange has commercial
          substance if the future cash flows of the entity are expected to change
          significantly as a result of the exchange. The Company does not expect
          the
          adoption of this statement will have any material impact on its results
          or
          financial position.
 
 In
          December 2004, the FASB issued SFAS No. 152, *Accounting
          for Real Estate Time-Sharing Transactions an amendment of FASB Statements
          No. 66
          and 67.* This
          Statement amends FASB
          Statement No. 66 , *Accounting for Sales of Real Estate,* to
          reference the financial accounting and reporting guidance for real estate
          time-sharing transactions that is provided in AICPA Statement of Position
          (SOP)
          04-2, *Accounting for Real Estate Time-Sharing Transactions.* This
          Statement also amends FASB
          Statement No. 67 , *Accounting for Costs and Initial Rental Operations of Real Estate
          Projects,* to state
          that the guidance for (a) incidental operations and (b) costs incurred
          to sell
          real estate projects does not apply to real estate time-sharing transactions.
          This Statement is effective for financial statements for fiscal years beginning
          after June 15, 2005. The guidelines of this statement are not applicable
          to the
          Company.
 
 SFAS
          No.
          154 (“SFAS 154”), *Accounting
          Changes and Error Corrections,* was
          issued in May 2005 and replaces APB Opinion No. 20 and SFAS No. 3 (“SFAS 3”).
          SFAS No. 154 requires retrospective application for voluntary changes in
          accounting principle in most instances and is required to be applied to
          all
          accounting changes made in fiscal years beginning after December 15, 2005.
          The
          Company’s expected January 1, 2006 adoption of SFAS No. 154 is not expected to
          have any material impact on its results or financial position.
 
 In
          February 2006, the FASB issued SFAS No. 155, “ *Accounting
          for Certain Hybrid Financial Instruments* ”
(SFAS
          155”), which amends SFAS No. 133, “Accounting for Derivatives Instruments and
          Hedging Activities” (“SFAS 133”) and SFAS No. 140, “ *Accounting
          for Transfers and Servicing of Financial Assets and Extinguishment of
          Liabilities* ”
(SFAS
          140”). SFAS 155 amends SFAS 133 to narrow the scope exception for interest-only
          and principal-only strips on debt instruments to include only such strips
          representing rights to receive a specified portion of the contractual interest
          or principle cash flows. SFAS 155 also amends SFAS 140 to allow qualifying
          special-purpose entities to hold a passive derivative financial instrument
          pertaining to beneficial interests that itself is a derivative instruments.
          The
          Company is currently evaluating the impact this new Standard, but believes
          that
          will not have that it will not have a material impact on the Company’s financial
          position
  10
 
 HUIFENG
          BIO-PHARMACEUTICAL TECHNOLOGY INC.
 (PREVIOUSLY
          SECURED DATA, INC.) AND SUBSIDIARIES
 NOTES
          TO
          THE CONSOLIDATED FINANCIAL STATEMENTS
 AS
          OF
          DECEMBER 31, 2005 AND 2004 (RESTATED)
  2. **RESTATEMENT
          OF FINANCIAL STATEMENTS**
 
 The
          Company originally recorded during the year ended December 31, 2004, the
          costs
          incurred by Huifeng Bio-pharmaceutical Technology Inc. (previously Secured
          Data,
          Inc.) prior to the reverse merger as expenses of the Company for that year.
          Under reverse merger accounting such costs should be treated as a reduction
          of
          additional paid in capital. The Company has restated these costs in the
          Balance
          Sheet, Statement of Operations, Statement of Stockholders’ Equity and the
          Statement of Cash Flows.
 
 A
          summary
          of significant effects of the restatement is as follows:
 
 December
                      31,2004
                  
                  December
                      31,(As
                      Previously
                  
                  2004Statement
                      of Operations
                  
                  Reported)
                  
                  (As
                      Restated)Net
                      sales
                  
                  $
                  2,478,763
                  
                  $
                  2,478,763Cost
                      of sales
                  
                  
                  (2,235,189
                  )
                  
                  (2,235,189
                  )Gross
                      profit
                  
                  
                  243,574
                  
                  
                  243,574Operating
                      expenses
                  
                  
                  964,637
                  
                  
                  465,923Loss
                      from operations
                  
                  
                  (721,063
                  )
                  
                  (222,349
                  )Other
                      income (expenses)
                  
                  
                  1,760
                  
                  
                  1,760Income
                      tax expense
                  
                  
                  (7,503
                  )
                  
                  (7,503
                  )Minority
                      interest
                  
                  
                  8,362
                  
                  
                  8,362Net
                      loss
                  
                  
                  (718,444
                  )
                  
                  (219,730
                  )Net
                      loss per share-basic and diluted
                  
                  $
                  (0.16
                  )
                  $
                  (0.049
                  )Weighted
                      average number of shares outstandingduring
                      the year-basic and diluted
                  
                  
                  4,506,870
                  
                  
                  4,506,870December
                      31,2004
                  
                  
                  December
                      31,(As
                      Previously
                  
                  
                  
                  
                  
                  2004Balance
                      sheet
                  
                  
                  Reported
                  )
                  
                  (As
                      Restated
                  )Current
                      assets
                  
                  $
                  1,971,231
                  
                  $
                  1,971,231Property
                      and equipment, net
                  
                  
                  879,503
                  
                  
                  879,503Land
                      use rights, net
                  
                  
                  133,974
                  
                  
                  133,974Other
                      assets
                  
                  
                  31,190
                  
                  
                  31,190Total
                      assets
                  
                  
                  3,015,898
                  
                  
                  3,015,898Current
                      liabilities
                  
                  
                  2,314,085
                  
                  
                  2,314,085Minority
                      interest
                  
                  
                  58,915
                  
                  
                  58,915Stockholders'
                      equity*Common
                      stock*
                  
                  
                  93,608
                  
                  
                  93,608*Additional
                      paid-in capital*
                  
                  
                  3,082,102
                  
                  
                  2,583,388*Retained
                      earnings (deficit)**Unappropriated*
                  
                  
                  (2,540,062
                  )
                  
                  (2,041,348
                  )*Appropriated*
                  
                  
                  7,250
                  
                  
                  7,250Total
                      liabilities and stockholders' equity
                  
                  $
                  3,015,898
                  
                  $
                  3,015,898
  11
  HUIFENG
          BIO-PHARMACEUTICAL TECHNOLOGY INC.
 (PREVIOUSLY
          SECURED DATA, INC.) AND SUBSIDIARIES
 NOTES
          TO
          THE CONSOLIDATED FINANCIAL STATEMENTS
 AS
          OF
          DECEMBER 31, 2005 AND 2004 (RESTATED)
 
 
 3. **ACQUISITION
          OF SUBSIDIARY**
 
 On
          May
          27, 2005, the Company’s subsidiary - Huifeng Biochemistry completed its 80.2%
          interest step acquisition of Huifeng Pharmaceutical. Under the purchase
          method
          of accounting, the total purchase price was allocated to Huifeng
          Pharmaceutical’s net tangible assets based upon the estimated fair values of the
          assets as of the date of completion of the acquisition.
 
 A
          summary
          of the fair value of net assets of Huifeng Pharmaceutical at the date of
          acquisition is as follows:
 
 Current
                      assets
                  
                  $
                  582,743Non-current
                      assets
                  
                  
                  1,526,118Total
                      assets
                  
                  
                  2,108,861Current
                      liabilities
                  
                  
                  (10,870
                  )Net
                      assets acquired
                  
                  
                  2,097,991Minority
                      interest
                  
                  
                  (415,088
                  )1,682,903Share
                      of pre-acquisition losses prior to becoming a subsidiary
                  
                  
                  3231,683,226Goodwill
                      acquired
                  
                  
                  2,764Consideration
                      paid
                  
                  $
                  1,685,990
  The
          unaudited pro forma information presents a summary of the results of operations
          of the Company assuming the acquisitions of Huifeng Pharmaceutical occurred
          at
          the beginning of each year is as follows:
  20042005
                  
                  (As
                      restated)Net
                      sales
                  
                  $
                  2,443,060
                  
                  $
                  2,478,763Net
                      (loss) income
                  
                  $
                  (813,008
                  )
                  $
                  87,441Net
                      (loss) income per share-basic and diluted
                  
                  $
                  (0.108
                  )
                  $
                  0.019
  4. **GOODWILL**
  20042005
                  
                  (As
                      restated)Cost
                      of goodwill acquired in step acquisition of a subsidiary
                  
                  $
                  2,764
                  
                  $
                  -Amount
                      written off
                  
                  
                  (2,764
                  )
                  
                  -$
                  -
                  
                  $
                  -
  12
  HUIFENG
          BIO-PHARMACEUTICAL TECHNOLOGY INC.
 (PREVIOUSLY
          SECURED DATA, INC.) AND SUBSIDIARIES
 NOTES
          TO
          THE CONSOLIDATED FINANCIAL STATEMENTS
 AS
          OF
          DECEMBER 31, 2005 AND 2004 (RESTATED)
 
 
 5. **ACCOUNTS
          RECEIVABLE**
 
 Accounts
          receivable at December 31, 2005 and 2004 consisted of the following:
  20042005
                  
                  (As
                      restated)Accounts
                      receivable
                  
                  $
                  1,171,574
                  
                  $
                  104,144Less:
                      allowance for doubtful accounts
                  
                  
                  (35,016
                  )
                  
                  -Accounts
                      receivable, net
                  
                  $
                  1,136,558
                  
                  $
                  104,144
  For
          the
          years ended December 31, 2005 and 2004, the Company recorded an allowance
          for
          doubtful accounts of $30,516 and $0 respectively.
  6. **LOANS
          RECEIVABLE**
 
 Loans
          receivable at December 31, 2005 and 2004 consisted of the
          followings:
  20042005
                  
                  (As
                      restated)Loan
                      receivable from a third party, interest rate of 12%
                  
                  $
                  185,643
                  
                  $
                  -per
                      annum, non-secured, due September 2006Loan
                      receivable from a third party, interest rate of 10%per
                      annum, non-secured, due November 2006
                  
                  
                  247,525
                  
                  
                  -$
                  433,168
                  
                  $
                  -
  Interest
          income in respect to loans receivable for the years ended December 31,
          2005 and
          2004 were $29,351 and $0 respectively.
  7. **INVENTORIES**
 
 Inventories
          at December 31, 2005 and 2004 consisted of the following:
  20042005
                  
                  (As
                      restated)Raw
                      materials
                  
                  $
                  158,838
                  
                  $
                  1,047,781Work-in-progress
                  
                  
                  7,575
                  
                  
                  11,917Finished
                      goods
                  
                  
                  759,368
                  
                  
                  242,327925,781
                  
                  
                  1,302,025Less:
                      provision of obsolescence
                  
                  
                  -
                  
                  
                  -$
                  925,781
                  
                  $
                  1,302,025
 For
          the
          year ended December 31, 2005 and 2004, the Company did not have any obsolete
          inventories.
  13
  HUIFENG
          BIO-PHARMACEUTICAL TECHNOLOGY INC.
 (PREVIOUSLY
          SECURED DATA, INC.) AND SUBSIDIARIES
 NOTES
          TO
          THE CONSOLIDATED FINANCIAL STATEMENTS
 AS
          OF
          DECEMBER 31, 2005 AND 2004 (RESTATED)
 
 
 8. **OTHER ASSETS**
 
 Other
          assets at December 31, 2005 and 2004 consisted of the following:
  20042005
                  
                  (As
                      restated)Short-term
                      note receivable
                  
                  $
                  -
                  
                  $
                  181,159Loans
                      interest receivable
                  
                  
                  51,980
                  
                  
                  -Advances
                      to staff
                  
                  
                  10,845
                  
                  
                  39,227Prepayments
                  
                  
                  23,522
                  
                  
                  63,018Trade
                      deposits paid
                  
                  
                  190,307
                  
                  
                  32,590Others
                  
                  
                  15,157
                  
                  
                  19,064$
                  291,811
                  
                  $
                  335,058
 9. **PROPERTY
          AND EQUIPMENT**
 
 The
          following is a summary of property and equipment at December 31, 2005 and
          2004:
 20042005
                    
                    (As
                        restated)Plant
                        and machinery
                    
                    $2,368,433
                    
                    $769,476Motor
                        vehicles
                    
                    
                    90,881
                    
                    
                    87,262Furniture
                        and office equipment
                    
                    
                    30,420
                    
                    
                    20,251Construction
                        in progress - factory building
                    
                    
                    483,739
                    
                    
                    286,0392,973,473
                    
                    
                    1,163,028Less:
                        accumulated depreciation
                    
                    
                    449,230
                    
                    
                    283,525Property
                        and equipment, net
                    
                    $
                    2,524,243
                    
                    $
                    879,503
  Depreciation
          expenses for the years ended December 31, 2005 and 2004 were $165,705 and
          $93,411 respectively.
  10. **LAND
          USE RIGHTS**
 
 Land
          use
          rights at December 31, 2005 and 2004 consisted of the
          following:
 20042005
                  
                  (As
                      restated)Land
                      use rights
                  
                  $
                  134,660
                  
                  $
                  134,660Less:
                      accumulated amortization
                  
                  
                  3,433
                  
                  
                  686Land
                      use rights, net
                  
                  $
                  131,227
                  
                  $
                  133,974
  Amortization
          expenses for the years ended December 31, 2005 and 2004 were $2,747 and
          $686
          respectively.
  14
  HUIFENG
          BIO-PHARMACEUTICAL TECHNOLOGY INC.
 (PREVIOUSLY
          SECURED DATA, INC.) AND SUBSIDIARIES
 NOTES
          TO
          THE CONSOLIDATED FINANCIAL STATEMENTS
 AS
          OF
          DECEMBER 31, 2005 AND 2004 (RESTATED)
 
 
 11. **INVESTMENT
          IN AFFILIATE**
 
 On
                    June 16, 2004, the Company’s subsidiary Xian Huifeng Biochemistry Group
                    Joint-Stock Company Limited (previously Xian Huifeng Biochemistry
                    Joint-Stock Company Limited (“Huifeng Biochemistry”) acquired an 86.7%
                    interest in Baoji Jinsen Pharmaceutical Company Limited, later
                    renamed to
                    Xian Huifeng Pharmaceutical Company Limited (“Huifeng Pharmaceutical”),
                    which owns licenses to manufacture two pharmaceutical products
                    in the PRC.
                    The balance of 13.3% is held by a stockholder of the Company.
                    On November
                    10, 2004 Huifeng Pharmaceutical increased its registered capital
                    from
                    $181,159 to $603,865. The increased registered capital was fully
                    subscribed by a stockholder of the Company, diluting the Company’s
                    interest in Huifeng Pharmaceutical from 86.7% to 26%. On May
                    27, 2005 the
                    PRC Government approved Huifeng Biochemistry’s increased investment in
                    Huifeng Pharmaceutical from $31,401 to $1,685,990 through an
                    increase in
                    the registered capital of Huifeng Pharmaceutical from $603,865
                    to
                    $2,258,454. The acquisition of Huifeng Pharmaceutical by Huifeng
                    Biochemistry was through a step process increasing Huifeng Biochemistry’s
                    interest in Huifeng Pharmaceutical from 26% to
                    80.2%.
 
 A summary of the financial statements of the affiliate as of December 31,
          2005
          and 2004 is as follows:
  20042005
                  
                  (As
                      restated)Current
                      assets
                  
                  $
                  -
                  
                  $
                  425,641Non-current
                      assets
                  
                  
                  -
                  
                  
                  1,086Total
                      assets
                  
                  
                  -
                  
                  
                  426,727Current
                      liabilities
                  
                  
                  -
                  
                  
                  4,831Stockholders'
                      equity
                  
                  
                  -
                  
                  
                  421,896Total
                      liabilities and stockholders' equity
                  
                  $
                  -
                  
                  $
                  426,727Revenue
                  
                  $
                  -
                  
                  $
                  -Net
                      loss from November 11, 2004 to December 31, 2004
                  
                  $
                  -
                  
                  $
                  (810
                  )Net
                      loss for the year ended December 31, 2005
                  
                  $
                  -
                  
                  $
                  -The
                      Company's share of the loss for 2005 and 2004 :Company
                      share at 26% and equity in loss of affiliate
                  
                  $
                  -
                  
                  $
                  (211
                  )
 
 12. **OTHER PAYABLES AND ACCRUED EXPENSES**
 
 Other payables and accrued liabilities at December 31, 2005 and 2004 consist
          of
          the following:
 20042005
                
                (As
                    restated)Other
                    payables
                
                $
                42,213
                
                $
                24,640Accrued
                    expenses
                
                
                106,590
                
                
                113,599Deposits
                    received from customers
                
                
                7,962
                
                
                6,952$
                156,765
                
                $
                145,191
  15
  HUIFENG
          BIO-PHARMACEUTICAL TECHNOLOGY INC.
 (PREVIOUSLY
          SECURED DATA, INC.) AND SUBSIDIARIES
 NOTES
          TO
          THE CONSOLIDATED FINANCIAL STATEMENTS
 AS
          OF
          DECEMBER 31, 2005 AND 2004 (RESTATED)
 
 13. **CONVERTIBLE
          NOTE PAYABLE**
 
 Note
          payable at December 31, 2005 and 2004 consists of the following:
  20042005
                  
                  (As
                      restated)Convertible
                      Promissory Note
                  
                  $
                  -
                  
                  $
                  1,900,000
 Pursuant
          to a Convertible Promissory Note, the Company promises to pay to Shareholders
          or
          their registered assigns, the principal sum of $1,900,000 on June 30, 2005
          or
          such earlier date as the Convertible Note is required or permitted to be
          repaid
          as provided hereunder the maturity date, and to pay interest to the Holders
          on
          the aggregate unconverted and then outstanding principal amount of this
          Convertible Note at the rate of 5% per annum, payable on the maturity date
          as
          set forth herein. Interest shall be calculated on the basis of a 360 day
          year
          and shall accrue on the maturity date. On the maturity date, the Company
          may, in
          its sole discretion, pay the principal sum by issuing to the Holder 10,465,725
          shares of the Company’s restricted common stock at $0.1815 per share, provided a
          required one for eighteen reverse stock split of the common stock has been
          effected. On June 30, 2005, the Company amended the due date of the Convertible
          Promissory Note from June 30, 2005 to December 31, 2005 with all other
          terms and
          conditions set forth in the Note remaining unchanged. On October 12, 2005,
          the
          Company issued 10,465,725 shares of restricted common stock in conversion
          of the
          Convertible Promissory Note of $1,900,000.
 
 14. **INCOME
          TAX**
 
 a Huifeng
          Bio-pharmaceutical was incorporated in the United States and has incurred
          net
          operating loss as for income tax purposes for 2005 and 2004.
 
 Northwest,
          wholly owned subsidiary of the Company, was incorporated in the British
          Virgin
          Islands and, under current law of the British Virgin Islands, is not subject
          to
          tax on income or on capital gains.
 
 Huifeng
          Biochemistry, wholly owned subsidiary of Northwest, was incorporated in
          the PRC
          being registered as a new and high technology enterprise is entitled to
          an
          income tax reduction. According to the document of reductions approved
          by the
          local tax bureau, the income tax rate was reduced from 33% to 15% on a
          permanent
          basis. No provision for income tax expenses for 2005 has been made as Huifeng
          Biochemistry has incurred net operating loss. The income tax expenses paid
          during 2005 of $253 represents underprovision for income tax for the year
          2004.
          The income tax expenses for 2004 were $7,503.
 
 Huifeng
          Engineering and Huifeng Pharmaceutical, wholly owned subsidiaries of Huifeng
          Biochemistry, were also incorporated in the PRC and subject to PRC income
          tax
          which is computed according to the relevant laws and regulations in the
          PRC. No
          provision for income tax expenses for 2005 and 2004 as Huifeng Engineering
          and
          Huifeng Pharmaceutical have incurred net operating loss.
 
 The
          income tax expenses for 2005 and 2004 are summarized as follows:
 
 
 20042005
                
                (As
                    restated)PRC
                    Income TaxCurrent
                
                $
                253
                
                $
                7,503$
                253
                
                $
                7,503
  16
  HUIFENG
          BIO-PHARMACEUTICAL TECHNOLOGY INC.
 (PREVIOUSLY
          SECURED DATA, INC.) AND SUBSIDIARIES
 NOTES
          TO
          THE CONSOLIDATED FINANCIAL STATEMENTS
 AS
          OF
          DECEMBER 31, 2005 AND 2004 (RESTATED)
 
 
 14. **INCOME
          TAX (CONTINUED)**
 
 b.  The
          Company’s deferred tax assets at December 31, 2005 and 2004 consist of net
          operating loss carry forwards calculated using statutory effective tax
          rates.
          Due to its history of losses, the Company determined that realization of
          its net
          deferred tax assets is currently judged to be unlikely rather than not.
          Consequently, the Company has provided a valuation allowance covering 100%
          of
          its net deferred tax assets.
 
 As
          of in
          December 31, 2005 and 2004, the Company had net operating loss carry forwards
          of
          approximately $737,172 and $20,000 respectively for U.S. income tax purposes
          available for offset against future taxable U.S. income, which expire 2025.
          The
          net changes in the valuation allowance for 2005 and 2004 were increases
          of
          $243,838 and $6,800 respectively.
 
 c.  The
          reconciliation of income taxes computed at the statutory income tax rates
          to
          total income taxes for the years ended December 31, 2005 and 2004 is as
          follows:
 
 20042005
                  
                  (As
                      restated)Huifeng
                      Bio-PharmaceuticalIncome
                      tax computed at the federal statutory rate
                  
                  
                  34
                  %
                  
                  34
                  %State
                      income taxes, net of federal tax benefit
                  
                  
                  0
                  %
                  
                  0
                  %Valuation
                      allowance
                  
                  
                  (34
                  %)
                  
                  (34
                  %)Total
                      deferred tax asset
                  
                  
                  0
                  %
                  
                  0
                  %
 15. **NET
          LOSS PER SHARE**
 
 The
          following is net loss per share information at December 31:
 
 20042005
                  
                  (As
                      restated)Net
                      loss
                  
                  $(832,767)
                  
                  $(219,730)Basic
                      and diluted weighted-average commonstock
                      outstanding
                  
                  $
                  7,529,550
                  
                  $
                  4,506,870Net
                      loss per share - basic and diluted
                  
                  $
                  (0.111
                  )
                  $
                  (0.049
                  )
  16. **COMMITMENTS
          AND CONTINGENCIES**
 
 (A)
                Employee
                    benefits
 
 The
          full
          time employees of the Company are entitled to employee benefits including
          medical care,  welfare
          subsidies, unemployment insurance and pension benefits through a Chinese
          government  mandated
          multi-employer defined contribution plan. The Company is required to accrue
          for
          those  benefits
          based on certain percentages of the employees’ salaries and make contributions
          to the plans  out
          of
          the amounts accrued for medical and pension benefits. The total provision
          and
          contributions  made
          for
          such employee benefits was $3,522 and $3,607 for the years ended December
          31,
          2005 and 2004, respectively. The Chinese government is responsible for
          the
          medical benefits and the pension  liability
          to be paid to these employees.
 
 17
  HUIFENG
          BIO-PHARMACEUTICAL TECHNOLOGY INC.
 (PREVIOUSLY
          SECURED DATA, INC.) AND SUBSIDIARIES
 NOTES
          TO
          THE CONSOLIDATED FINANCIAL STATEMENTS
 AS
          OF
          DECEMBER 31, 2005 AND 2004 (RESTATED)
 
 
 16. **COMMITMENTS AND CONTINGENCIES (CONTINUED)**
 
 (B)
                Commitments
  The
          Company occupies office and storage spaces from a third party under operating
          leases which expires on March 31, 2006 and November 10, 2006 at a quarterly
          rental of $3,156 and $356 respectively. Accordingly, for 2005 and 2004,
          the
          Company recognized rental expense for these spaces in the amount of $12,816
          and
          $12,319, respectively.
 
 As
          of
          December 31, 2005, the Company has outstanding commitments with respect
          to
          non-cancelable operating leases, which are due as follows:
  2006
                  
                  $
                  4,225
  17. **SHAREHOLDERS’ EQUITY**
 
 **(A)
          Stock issuances**
 
 On
          December 20, 2004 the Company entered into an Agreement and Plan of
          Reorganization with Northwest Bio-Technic Inc (“Northwest”) to acquire 100% of
          Northwest equity. The Company issued 4,485,318 shares in exchange for 30%
          of
          Northwest’s outstanding shares.
 
 The
          Company has authorized up to 5,000,000 shares of preferred stock with a
          par
          value of $0.001 per share. The preferred stock can be issued in various
          series
          with varying dividend rates and preferences. At December 31, 2004 there
          are no
          issued series or shares of preferred stock.
 
 In
          October 2005, the Company effected a one for eighteen reverse split of
          its
          common stock that resulted in a reduction of the number of issued and
          outstanding shares from 93,604,958 to approximately 5,200,444 shares.
 
 On
          the
          effective date of the reverse split of its common stock, the Company decreased
          the par value of its common stock from $0.001 to $0.000555 instead of increasing
          the par value of its common stock from $0.001 to $0.018. The Company corrected
          this situation by filing an amendment to its Articles of Incorporation
          on March
          28, 2005 to increase the par value of its common stock from $0.000555 to
          $0.018.
          The issued capital was retroactively adjusted to reflect the increase in
          the par
          value of the common stock.
 
 On
          October 12, 2005, the Company issued 10,465,725 shares of restricted common
          stock in conversion of the Convertible Promissory Note of
          $1,900,000.
 
 In
          December 2005, the Company approved the issue of 800,000 shares of common
          stock
          having a fair value of $560,000 to four staff as stock bonuses. As of December
          31, 2005, these shares have not been issued.
 
 **(B)**  **Appropriated
          retained earnings**
 
 The
          Company’s wholly owned subsidiary, Huifeng Biochemistry is required to make
          appropriations to reserves funds, comprising the statutory surplus reserve,
          statutory public welfare fund and discretionary surplus reserve, based
          on
          after-tax net income determined in accordance with generally accepted accounting
          principles of the People’s Republic of China (the “PRC GAAP”). Appropriation to
          the statutory surplus reserve should be at least 10% of the after tax net
          income
          determined in accordance with the PRC GAAP until the reserve is equal to
          50% of
          the entities’ registered capital. Appropriations to the statutory public welfare
          fund are at 5% to 10% of the after tax net income determined in accordance
          with
          the PRC GAAP. The statutory public welfare fund is established for the
          purpose
          of providing employee facilities and other collective benefits to the employees
          and is non-distributable other than in liquidation. Appropriations to the
          discretionary surplus reserve are made at the discretion of the Board of
          Directors.
 
 During
          2005 and 2004, the Company’s wholly owned subsidiary Huifeng Biochemistry
          appropriated $16,024 and $7,167, respectively to the reserves funds based
          on its
          net income under PRC GAAP.
  18
 
 HUIFENG
          BIO-PHARMACEUTICAL TECHNOLOGY INC.
 (PREVIOUSLY
          SECURED DATA, INC.) AND SUBSIDIARIES
 NOTES
          TO
          THE CONSOLIDATED FINANCIAL STATEMENTS
 AS
          OF
          DECEMBER 31, 2005 AND 2004 (RESTATED)
 
 
 18. **RELATED PARTY TRANSACTIONS**
 As
          of
          December 31, 2005 and 2004, the stockholders owed the Company $100,007
          and
          $62,493 respectively for advances made on an unsecured basis and repayable
          on
          demand. Interest is charged at 6% per annum on the amount due. Total interest
          income amounted to $5,664 and $0 for the years ended December 31, 2005
          and 2004,
          respectively.
 
 As
          of
          December 31, 2005 and 2004, the Company also owed the stockholders $1,239
          and
          $193,433 respectively for advances made on an unsecured basis, free of
          interest
          payment and repayable on demand.
 
 During
          2004, the Company issued 346,238 shares of common stock having a fair value
          of
          $349,008 at $1.008 to a shareholder as repayment of cash advances of $373,937
          to
          operate the Company’s business. The Company recognized operating expenses of
          $373,937 as of December 31, 2004.
 
 The
          Company issued a Convertible Promissory Note of $1,900,000 to the shareholders
          of Northwest, the Note is convertible into 10,465,725 (post a one for eighteen
          reverse split) shares to exchange for 70% of the outstanding shares of
          Northwest. On October 12, 2005, the Company issued 10,465,725 shares of
          restricted common stock in conversion of the Convertible Promissory Note
          of
          $1,900,000.
 
 See
          Note
          1 (A) for transactions with Huifeng Bio-pharmaceutical and its
          subsidiaries.
 
 19. **CONCENTRATIONS AND RISKS**
 
 
 During
          2005 and 2004, 100% of the Company’s assets were located in China.
 
 During
          2005 and 2004, 65% and 90% of the Company’s revenues were derived from companies
          located in China respectively.
 
 The
          Company relied on two customers for approximately $644,641 and $315,613
          respectively representing in aggregate 39% of sales for the year ended
          December
          31, 2005, and relied on two customers for approximately $790,217 and $802,324
          respectively representing in aggregate 63% of sales for the year ended
          December
          31, 2004. At December 31, 2005 and 2004, accounts receivable from those
          customers totaled $340,302 and $32,119 respectively.
 
 The
          Company also relied on one supplier for approximately $181,743 representing
          in
          aggregate 14% of purchases for the year ended December 31, 2005, and relied
          on
          four suppliers for approximately $443,718, $269,547, $288,832 and $339,895
          respectively representing in aggregate 62% of purchases for the year ended
          December 31, 2004. At December 31, 2005 and 2004, accounts payable to those
          two
          suppliers totaled $29,576 and $1,182 respectively.
 
 20. **SUBSEQUENT
          EVENT**
 
 On
          March
          28, 2006, the Company filed an amendment to its Articles of Incorporation
          to
          increase the par value of its common stock from $0.000555 to
          $0.018.
  19